1. K/DOQI clinical practice guidelines for chronic kidney disease: Evaluation, classification, and stratification. Kidney Disease Outcome Quality Initiative. Am J Kidney Dis 39:S1-S266, 2002 (suppl 2)
2. US Renal Data System. USRDS 2000 Annual Report, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases. Bethesda, MD, 2000
3. Levey AS, Beto JA, Coronado BE, Eknoyan G, Foley RN, Kasiske BL, Klag MJ, Mailloux LU, Manske CL, Meyer KB, Parfrey PS, Pfeffer MA, Wenger NK, Wilson PW, Wright JT Jr: Controlling the epidemic of cardiovascular disease in chronic renal disease: what do we know? What do we need to learn? Where do we go from here? National Kidney Foundation Task Force on Cardiovascular Disease. Am J Kidney Dis 32:853-906, 1998
4. Levey AS: Controlling the epidemic of cardiovascular disease in chronic renal disease: Where do we start? Am J Kidney Dis 32:S5-S13, 1998 (suppl 3)
5. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr, Jones DW, Materson BJ, Oparil S, Wright JT Jr, Roccella EJ: The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: The JNC 7 report. JAMA 289:2560-2572, 2003
5a. Chobanian AV, Barkris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr, Jones DW, Materson BJ, Oparil S, Wright JT Jr, Roccella EJ: Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension 42:1206-1252, 2003
6. Standards of medical care for patients with diabetes mellitus. Diabetes Care 26:S33-S50, 2003 (suppl 1)
7. Sarnak MJ, Levey AS, Schoolwerth AC, Coresh J, Culleton B, Hamm HL, McCullough PA, Kasiske BL, Kelepouris E, Klag MJ, Parfrey PS, Pfeffer M, Raij L, Spinosa DJ, Wilson PW: Kidney disease as a risk factor for development of cardiovascular disease. A statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology and Epidemiology and Prevention. Circulation 108:2154-2169, 2003
8. Hillege HL, Fidler V, Diercks GF, van Gilst WH, de Zeeuw D, van Veldhuisen DJ, Gans RO, Janssen WM, Grobbee DE, de Jong PE: Urinary albumin excretion predicts cardiovascular and noncardiovascular mortality in general population. Circulation 106:1777-1782, 2002
9. Manjunath G, Tighiouart H, Ibrahim H, MacLeod B, Salem DN, Griffith JL, Coresh J, Levey AS, Sarnak MJ: Level of kidney function as a risk factor for atherosclerotic cardiovascular outcomes in the community. J Am Coll Cardiol 41:47-55, 2003
10. NIH, NHLBI: Update on the Task Force report (1987) on high blood pressure in children and adolescents: A working group report from the National High Blood Pressure Education Program. NIH Publication No. 96-3790, 1996
11. Woolf SH: Manual for Clinical Practice Guideline Development. Rockville, MD, US Department of Health and Human Services, Public Health Service, Agency for Health Care Policy and Research, 1991
12. Coronado BE, Bu D, Levey AS, Meyer KB: Methods of literature review and synthesis. Am J Kidney Dis 32:S14-S55, 1998 (suppl 3)
13. Levey AS, Coresh J, Balk E, Kausz AT, Levin A, Steffes MW, Hogg RJ, Perrone RD, Lau J, Eknoyan G: National Kidney Foundation practice guidelines for chronic kidney disease: Evaluation, classification, and stratification. Ann Intern Med 139:137-147, 2003
14. National Kidney Foundation: K/DOQI clinical practice guidelines for managing dyslipidemias in chronic kidney disease. Am J Kidney Dis 41:S1-S91, 2003 (suppl 3)
15. The sixth report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure. Arch Intern Med 157:2413-2446, 1997
16. Coresh J, Astor BC, Greene T, Eknoyan G, Levey AS: Prevalence of chronic kidney disease and decreased kidney function in the adult US population: Third National Health and Nutrition Examination Survey. Am J Kidney Dis 41:1-12, 2003
17. USRDS 2001 Annual Data Report: Atlas of End-Stage Renal Disease in the United States, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases. Bethesda, MD, US Renal Data System, 2001
18. Warram JH, Gearin G, Laffel L, Krolewski AS: Effect of duration of type I diabetes on the prevalence of stages of diabetic nephropathy defined by urinary albumin/creatinine ratio. J Am Soc Nephrol 7:930-937, 1996
19. Jacobs DR Jr, Murtaugh MA, Steffes M, Yu X, Roseman J, Goetz FC: Gender- and race-specific determination of albumin excretion rate using albumin-to-creatinine ratio in single, untimed urine specimens: The Coronary Artery Risk Development in Young Adults Study. Am J Epidemiol 155:1114-1119, 2002
20. Levey AS, Coresh J: Should the K/DOQI definition of chronic kidney disease be changed? CON (editorial). Am J Kidney Dis 42:623-625, 2003
21. Buckalew VM Jr, Berg RL, Wang SR, Porush JG, Rauch S, Schulman G: Prevalence of hypertension in 1,795 subjects with chronic renal disease: the modification of diet in renal disease study baseline cohort. Modification of Diet in Renal Disease Study Group. Am J Kidney Dis 28:811-821, 1996
22. Mailloux LU, Levey AS: Hypertension in patients with chronic renal disease. Am J Kidney Dis 32:S120-S141, 1998 (suppl 3)
23. Coresh J, Wei GL, McQuillan G, Brancati FL, Levey AS, Jones C, Klag MJ: Prevalence of high blood pressure and elevated serum creatinine level in the United States: Findings from the third National Health and Nutrition Examination Survey (1988-1994). Arch Intern Med 161:1207-1216, 2001
24. Foley RN, Parfrey PS, Sarnak MJ: Clinical epidemiology of cardiovascular disease in chronic renal disease. Am J Kidney Dis 32:S112-S119, 1998 (suppl 3)
25. Sarnak MJ, Levey AS: Cardiovascular disease and chronic renal disease: A new paradigm. Am J Kidney Dis 35:S117-S131, 2000 (suppl 1)
26. Parfrey PS, Foley RN: The clinical epidemiology of cardiac disease in chronic renal failure. J Am Soc Nephrol 10:1606-1615, 1999
27. McCullough PA: Why is chronic kidney disease the "spoiler" for cardiovascular outcomes? J Am Coll Cardiol 41:725-728, 2003
28. Stehouwer CD, Gall MA, Twisk JW, Knudsen E, Emeis JJ, Parving HH: Increased urinary albumin excretion, endothelial dysfunction, and chronic low-grade inflammation in type 2 diabetes: Progressive, interrelated, and independently associated with risk of death. Diabetes 51:1157-1165, 2002
29. Gerstein HC, Mann JF, Yi Q, Zinman B, Dinneen SF, Hoogwerf B, Halle JP, Young J, Rashkow A, Joyce C, Nawaz S, Yusuf S: Albuminuria and risk of cardiovascular events, death, and heart failure in diabetic and nondiabetic individuals. JAMA 286:421-426, 2001
30. Agewall S, Wikstrand J, Ljungman S, Fagerberg B: Usefulness of microalbuminuria in predicting cardiovascular mortality in treated hypertensive men with and without diabetes mellitus. Risk Factor Intervention Study Group. Am J Cardiol 80:164-169, 1997
31. Stephenson JM, Kenny S, Stevens LK, Fuller JH, Lee E: Proteinuria and mortality in diabetes: The WHO Multinational Study of Vascular Disease in Diabetes. Diabet Med 12:149-155, 1995
32. Dinneen SF, Gerstein HC: The association of microalbuminuria and mortality in non-insulin-dependent diabetes mellitus. A systematic overview of the literature. Arch Intern Med 157:1413-1418, 1997
33. Mogensen CE: Microalbuminuria predicts clinical proteinuria and early mortality in maturity-onset diabetes. N Engl J Med 310:356-360, 1984
34. Valmadrid CT, Klein R, Moss SE, Klein BE: The risk of cardiovascular disease mortality associated with microalbuminuria and gross proteinuria in persons with older-onset diabetes mellitus. Arch Intern Med 160:1093-1100, 2000
35. Miettinen H, Haffner SM, Lehto S, Ronnemaa T, Pyorala K, Laakso M: Proteinuria predicts stroke and other atherosclerotic vascular disease events in nondiabetic and non-insulin-dependent diabetic subjects. Stroke 27:2033-2039, 1996
36. Messent JW, Elliott TG, Hill RD, Jarrett RJ, Keen H, Viberti GC: Prognostic significance of microalbuminuria in insulin-dependent diabetes mellitus: A twenty-three year follow-up study. Kidney Int 41:836-839, 1992
37. Rossing P, Hougaard P, Borch-Johnsen K, Parving HH: Predictors of mortality in insulin dependent diabetes: 10 year observational follow up study. BMJ 313:779-784, 1996
38. Gall MA, Borch-Johnsen K, Hougaard P, Nielsen FS, Parving HH: Albuminuria and poor glycemic control predict mortality in NIDDM. Diabetes 44:1303-1309, 1995
39. Uusitupa MI, Niskanen LK, Siitonen O, Voutilainen E, Pyorala K: Ten-year cardiovascular mortality in relation to risk factors and abnormalities in lipoprotein composition in type 2 (non-insulin-dependent) diabetic and non-diabetic subjects. Diabetologia 36:1175-1184, 1993
40. Diercks GF, Hillege HL, van Boven AJ, Kors JA, Crijns HJ, Grobbee DE, de Jong PE, van Gilst WH: Microalbuminuria modifies the mortality risk associated with electrocardiographic ST-T segment changes. J Am Coll Cardiol 40:1401, 2002
41. De Leeuw PW, Thijs L, Birkenhager WH, Voyaki SM, Efstratopoulos AD, Fagard RH, Leonetti G, Nachev C, Petrie JC, Rodicio JL, Rosenfeld JJ, Sarti C, Staessen JA: Prognostic significance of renal function in elderly patients with isolated systolic hypertension: Results from the Syst-Eur trial. J Am Soc Nephrol 13:2213-2222, 2002
42. Ljungman S, Wikstrand J, Hartford M, Berglund G: Urinary albumin excretion—A predictor of risk of cardiovascular disease. A prospective 10-year follow-up of middle-aged nondiabetic normal and hypertensive men. Am J Hypertens 9:770-778, 1996
43. Damsgaard EM, Froland A, Jorgensen OD, Mogensen CE: Microalbuminuria as predictor of increased mortality in elderly people. BMJ 300:297-300, 1990
44. Grimm RH Jr, Svendsen KH, Kasiske B, Keane WF, Wahi MM: Proteinuria is a risk factor for mortality over 10 years of follow-up. MRFIT Research Group. Multiple Risk Factor Intervention Trial. Kidney Int Suppl 63:S10-S14, 1997
45. Yudkin JS, Forrest RD, Jackson CA: Microalbuminuria as predictor of vascular disease in non-diabetic subjects. Islington Diabetes Survey. Lancet 2:530-533, 1988
46. Culleton BF, Larson MG, Parfrey PS, Kannel WB, Levy D: Proteinuria as a risk factor for cardiovascular disease and mortality in older people: A prospective study. Am J Med 109:1-8, 2000
47. Jager A, Kostense PJ, Ruhe HG, Heine RJ, Nijpels G, Dekker JM, Bouter LM, Stehouwer CD: Microalbuminuria and peripheral arterial disease are independent predictors of cardiovascular and all-cause mortality, especially among hypertensive subjects: Five-year follow-up of the Hoorn Study. Arterioscler Thromb Vasc Biol 19:617-624, 1999
48. Roest M, Banga JD, Janssen WM, Grobbee DE, Sixma JJ, de Jong PE, de Zeeuw D, van Der Schouw YT: Excessive urinary albumin levels are associated with future cardiovascular mortality in postmenopausal women. Circulation 103:3057-3061, 2001
49. Kuusisto J, Mykkanen L, Pyorala K, Laakso M: Hyperinsulinemic microalbuminuria. A new risk indicator for coronary heart disease. Circulation 91:831-837, 1995
50. Ordonez JD, Hiatt RA, Killebrew EJ, Fireman BH: The increased risk of coronary heart disease associated with nephrotic syndrome. Kidney Int 44:638-642, 1993
51. Wagner DK, Harris T, Madans JH: Proteinuria as a biomarker: Risk of subsequent morbidity and mortality. Environ Res 66:160-172, 1994
52. Muntner P, He J, Hamm L, Loria C, Whelton PK: Renal insufficiency and subsequent death resulting from cardiovascular disease in the United States. J Am Soc Nephrol 13:745-753, 2002
53. Kannel WB, Stampfer MJ, Castelli WP, Verter J: The prognostic significance of proteinuria: The Framingham study. Am Heart J 108:1347-1352, 1984
54. Dries DL, Exner DV, Domanski MJ, Greenberg B, Stevenson LW: The prognostic implications of renal insufficiency in asymptomatic and symptomatic patients with left ventricular systolic dysfunction. J Am Coll Cardiol 35:681-689, 2000
55. Kearney MT, Fox KA, Lee AJ, Prescott RJ, Shah AM, Batin PD, Baig W, Lindsay S, Callahan TS, Shell WE, Eckberg DL, Zaman AG, Williams S, Neilson JM, Nolan J: Predicting death due to progressive heart failure in patients with mild-to-moderate chronic heart failure. J Am Coll Cardiol 40:1801-1808, 2002
56. McClellan WM, Flanders WD, Langston RD, Jurkovitz C, Presley R: Anemia and renal insufficiency are independent risk factors for death among patients with congestive heart failure admitted to community hospitals: a population-based study. J Am Soc Nephrol 13:1928-1936, 2002
57. Hillege HL, Girbes AR, de Kam PJ, Boomsma F, de Zeeuw D, Charlesworth A, Hampton Jr, van Veldhuisen DJ: Renal function, neurohormonal activation, and survival in patients with chronic heart failure. Circulation 102:203-210, 2000
58. Mahon NG, Blackstone EH, Francis GS, Starling RC 3rd, Young JB, Lauer MS: The prognostic value of estimated creatinine clearance alongside functional capacity in ambulatory patients with chronic congestive heart failure. J Am Coll Cardiol 40:1106-1113, 2002
59. McCullough PA, Soman SS, Shah SS, Smith ST, Marks KR, Yee J, Borzak S: Risks associated with renal dysfunction in patients in the coronary care unit. J Am Coll Cardiol 36:679-684, 2000
60. Soman SS, Sandberg KR, Borzak S, Hudson MP, Yee J, McCullough PA: The independent association of renal dysfunction and arrhythmias in critically ill patients. Chest 122:669-677, 2002
61. Matts JP, Karnegis JN, Campos CT, Fitch LL, Johnson JW, Buchwald H: Serum creatinine as an independent predictor of coronary heart disease mortality in normotensive survivors of myocardial infarction. POSCH Group. J Fam Pract 36:497-503, 1993
62. Walsh CR, O’Donnell CJ, Camargo CA Jr, Giugliano RP, Lloyd-Jones DM: Elevated serum creatinine is associated with 1-year mortality after acute myocardial infarction. Am Heart J 144:1003-1011, 2002
63. Beattie JN, Soman SS, Sandberg KR, Yee J, Borzak S, Garg M, McCullough PA: Determinants of mortality after myocardial infarction in patients with advanced renal dysfunction. Am J Kidney Dis 37:1191-1200, 2001
64. Shlipak MG, Heidenreich PA, Noguchi H, Chertow GM, Browner WS, McClellan MB: Association of renal insufficiency with treatment and outcomes after myocardial infarction in elderly patients. Ann Intern Med 137:555-562, 2002
65. Wright RS, Reeder GS, Herzog CA, Albright RC, Williams BA, Dvorak DL, Miller WL, Murphy JG, Kopecky SL, Jaffe AS: Acute myocardial infarction and renal dysfunction: A high-risk combination. Ann Intern Med 137:563-570, 2002
66. McCullough PA, Nowak RM, Foreback C, Tokarski G, Tomlanovich MC, Khoury N, Weaver WD, Sandberg KR, McCord J: Emergency evaluation of chest pain in patients with advanced kidney disease. Arch Intern Med 162:2464-2468, 2002
67. Al Suwaidi J, Reddan DN, Williams K, Pieper KS, Harrington RA, Califf RM, Granger CB, Ohman EM, Holmes DR Jr: Prognostic implications of abnormalities in renal function in patients with acute coronary syndromes. Circulation 106:974-980, 2002
68. Freeman RV, Mehta RH, Al Badr W, Cooper JV, Kline-Rogers E, Eagle KA: Influence of concurrent renal dysfunction on outcomes of patients with acute coronary syndromes and implications of the use of glycoprotein IIb/IIIa inhibitors. J Am Coll Cardiol 41:718-724, 2003
69. Wison S, Foo K, Cunningham J, Cooper J, Deaner A, Knight C, Ranjadayalan K, Timmis AD: Renal function and risk stratification in acute coronary syndromes. Am J Cardiol 91:1051-1054, 2003
70. Januzzi JL Jr, Snapinn SM, DiBattiste PM, Jang IK, Theroux P: Benefits and safety of tirofiban among acute coronary syndrome patients with mild to moderate renal insufficiency: Results from the Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms (PRISM-PLUS) trial. Circulation 105:2361-2366, 2002
71. Best PJ, Lennon R, Ting HH, Bell MR, Rihal CS, Holmes DR, Berger PB: The impact of renal insufficiency on clinical outcomes in patients undergoing percutaneous coronary interventions. J Am Coll Cardiol 39:1113-1119, 2002
72. Shaw RE, Anderson HV, Brindis RG, Krone RJ, Klein LW, McKay CR, Block PC, Shaw LJ, Hewitt K, Weintraub WS: Development of a risk adjustment mortality model using the American College of Cardiology-National Cardiovascular Data Registry (ACC-NCDR) experience: 1998-2000. J Am Coll Cardiol 39:1104-1112, 2002
73. Rubenstein MH, Harrell LC, Sheynberg BV, Schunkert H, Bazari H, Palacios IF: Are patients with renal failure good candidates for percutaneous coronary revascularization in the new device era? Circulation 102:2966-2972, 2000
74. Reinecke H, Trey T, Matzkies F, Fobker M, Breithardt G, Schaefer RM: Grade of chronic renal failure, and acute and long-term outcome after percutaneous coronary interventions. Kidney Int 63:696-701, 2003
75. Szczech LA, Reddan DN, Owen WF, Califf R, Racz M, Jones RH, Hannan EL: Differential survival after coronary revascularization procedures among patients with renal insufficiency. Kidney Int 60:292-299, 2001
76. Szczech LA, Best PJ, Crowley E, Brooks MM, Berger PB, Bittner V, Gersh BJ, Jones R, Califf RM, Ting HH, Whitlow PJ, Detre KM, Holmes D: Outcomes of patients with chronic renal insufficiency in the bypass angioplasty revascularization investigation. Circulation 105:2253-2258, 2002
77. Gruberg L, Weissman NJ, Waksman R, Laird JR Jr, Pinnow EE, Wu H, Deible R, Kent KM, Pichard AD, Satler LF, Lindsay J Jr: Comparison of outcomes after percutaneous coronary revascularization with stents in patients with and without mild chronic renal insufficiency. Am J Cardiol 89:54-57, 2002
78. Gruberg L, Weissman NJ, Pichard AD, Waksman R, Kent KM, Satler LF, Suddath WO, Pinnow EE, Gevorkian N, Lindsay J Jr: Impact of renal function on morbidity and mortality after percutaneous aortocoronary saphenous vein graft intervention. Am Heart J 145:529-534, 2003
79. Anderson RJ, O’Brien M, MaWhinney S, VillaNueva CB, Moritz TE, Sethi GK, Henderson WG, Hammermeister KE, Grover FL, Shroyer AL: Renal failure predisposes patients to adverse outcome after coronary artery bypass surgery. VA Cooperative Study #5. Kidney Int 55:1057-1062, 1999
80. Beddhu S, Allen-Brady K, Cheung AK, Horne BD, Bair T, Muhlestein JB, Anderson JL: Impact of renal failure on the risk of myocardial infarction and death. Kidney Int 62:1776-1783, 2002
81. Hemmelgarn BR, Ghali WA, Quan H, Brant R, Norris CM, Taub KJ, Knudtson ML: Poor long-term survival after coronary angiography in patients with renal insufficiency. Am J Kidney Dis 37:64-72, 2001
82. Shlipak MG, Simon JA, Grady D, Lin F, Wenger NK, Furberg CD: Renal insufficiency and cardiovascular events in postmenopausal women with coronary heart disease. J Am Coll Cardiol 38:705-711, 2001
83. Mann JF, Gerstein HC, Pogue J, Bosch J, Yusuf S: Renal insufficiency as a predictor of cardiovascular outcomes and the impact of ramipril: The HOPE randomized trial [see comments]. Ann Intern Med 134:629-636, 2001
84. Anderson RJ, O’Brien M, MaWhinney S, VillaNueva CB, Moritz TE, Sethi GK, Henderson WG, Hammermeister KE, Grover FL, Shroyer AL: Mild renal failure is associated with adverse outcome after cardiac valve surgery. Am J Kidney Dis 35:1127-1134, 2000
85. Fried LP, Kronmal RA, Newman AB, Bild DE, Mittelmark MB, Polak JF, Robbins JA, Gardin JM: Risk factors for 5-year mortality in older adults: The Cardiovascular Health Study. JAMA 279:585-592, 1998
86. Manjunath G, Tighiouart H, Coresh J, Macleod B, Salem DN, Griffith JL, Levey AS, Sarnak MJ: Level of kidney function as a risk factor for cardiovascular outcomes in the elderly. Kidney Int 63:1121-1129, 2003
87. Manolio TA, Kronmal RA, Burke GL, O’Leary DH, Price TR: Short-term predictors of incident stroke in older adults. The Cardiovascular Health Study. Stroke 27:1479-1486, 1996
88. Gottdiener JS, Arnold AM, Aurigemma GP, Polak JF, Tracy RP, Kitzman DW, Gardin JM, Rutledge JE, Boineau RC: Predictors of congestive heart failure in the elderly: The Cardiovascular Health Study. J Am Coll Cardiol 35:1628-1637, 2000
89. Ruilope LM, Salvetti A, Jamerson K, Hansson L, Warnold I, Wedel H, Zanchetti A: Renal function and intensive lowering of blood pressure in hypertensive participants of the hypertension optimal treatment (HOT) study. J Am Soc Nephrol 12:218-225, 2001
90. Schillaci G, Reboldi G, Verdecchia P: High-normal serum creatinine concentration is a predictor of cardiovascular risk in essential hypertension. Arch Intern Med 161:886-891, 2001
91. Henry RM, Kostense PJ, Bos G, Dekker JM, Nijpels G, Heine RJ, Bouter LM, Stehouwer CD: Mild renal insufficiency is associated with increased cardiovascular mortality: The Hoorn Study. Kidney Int 62:1402-1407, 2002
92. Flack JM, Neaton JD, Daniels B, Esunge P: Ethnicity and renal disease: Lessons from the Multiple Risk Factor Intervention Trial and the Treatment of Mild Hypertension Study. Am J Kidney Dis 21:31-40, 1993
93. Shulman NB, Ford CE, Hall WD, Blaufox MD, Simon D, Langford HG, Schneider KA: Prognostic value of serum creatinine and effect of treatment of hypertension on renal function. Results from the hypertension detection and follow-up program. The Hypertension Detection and Follow-up Program Cooperative Group. Hypertension 13:I80-I93, 1989 (suppl 5)
94. O’Brien MM, Gonzales R, Shroyer AL, Grunwald GK, Daley J, Henderson WG, Khuri SF, Anderson RJ: Modest serum creatinine elevation affects adverse outcome after general surgery. Kidney Int 62:585-592, 2002
95. Garg AX, Clark WF, Haynes RB, House AA: Moderate renal insufficiency and the risk of cardiovascular mortality: Results from the NHANES I. Kidney Int 61:1486-1494, 2002
96. Culleton BF, Larson MG, Wilson PW, Evans JC, Parfrey PS, Levy D: Cardiovascular disease and mortality in a community-based cohort with mild renal insufficiency. Kidney Int 56:2214-2219, 1999
97. Wannamethee SG, Shaper AG, Perry IJ: Serum creatinine concentration and risk of cardiovascular disease: A possible marker for increased risk of stroke. Stroke 28:557-563, 1997
98. Hunsicker LG, Adler S, Caggiula A, England BK, Greene T, Kusek JW, Rogers NL, Teschan PE: Predictors of the progression of renal disease in the Modification of Diet in Renal Disease Study. Kidney Int 51:1908-1919, 1997
99. Brenner BM, Meyer TW, Hostetter TH: Dietary protein intake and the progressive nature of kidney disease: The role of hemodynamically mediated glomerular injury in the pathogenesis of progressive glomerular sclerosis in aging, renal ablation, and intrinsic renal disease. N Engl J Med 307:652-659, 1982
100. Remuzzi G, Bertani T: Is glomerulosclerosis a consequence of altered glomerular permeability to macromolecules? Kidney Int 38:384-394, 1990
101. Stroebel RJ, Broers JK, Houle SK, Scott CG, Naessens JM: Improving hypertension control: A team approach in a primary care setting. Jt Comm J Qual Improv 26:623-632, 2000
102. Mensah GA: Refining strategies for the prevention and control of hypertension and related complications. Ethn Dis 9:327-332, 1999
103. Gaede P, Vedel P, Parving HH, Pedersen O: Intensified multifactorial intervention in patients with type 2 diabetes mellitus and microalbuminuria: The Steno type 2 randomised study. Lancet 353:617-622, 1999
104. Gaede P, Vedel P, Larsen N, Jensen GV, Parving HH, Pedersen O: Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med 348:383-393, 2003
105. Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G: Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 342:145-153, 2000
106. Wing LM, Reid CM, Ryan P, Beilin LJ, Brown MA, Jennings GL, Johnston CI, McNeil JJ, Macdonald GJ, Marley JE, Morgan TO, West MJ: A comparison of outcomes with angiotensin-converting–enzyme inhibitors and diuretics for hypertension in the elderly. N Engl J Med 348:583-592, 2003
107. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 288:2981-2997, 2002
108. Diagnosis and management of hypertension in the primary care setting. Washington, DC, Department of Veterans Affairs, 1999
109. Management of diabetes mellitus in the primary care setting. Washington, DC, Department of Veterans Affairs, 1999
110. Kasiske BL, Vazquez MA, Harmon WE, Brown RS, Danovitch GM, Gaston RS, Roth D, Scandling JD, Singer GG: Recommendations for the outpatient surveillance of renal transplant recipients. American Society of Transplantation. J Am Soc Nephrol 11:S1-S86, 2000 (suppl 15)
111. Primary care guidelines for the management of core aspects of diabetes care. Wellington, New Zealand, New Zealand Guidelines Group (NZGG), 2000
112. Bakris GL, Williams M, Dworkin L, Elliott WJ, Epstein M, Toto R, Tuttle K, Douglas J, Hsueh W, Sowers J: Preserving renal function in adults with hypertension and diabetes: A consensus approach. National Kidney Foundation Hypertension and Diabetes Executive Committees Working Group. Am J Kidney Dis 36:646-661, 2000
113. VHA/DoD clinical practice guideline for the management of chronic kidney disease and pre-ESRD in the primary care setting. Washington, DC, Veterans Health Administration, 2001
114. Hypertension in older people. A national clinical guideline. Edinburgh, Scotland, Scottish Intercollegiate Guidelines Network (SIGN), 2001
115. Standards of medical care for patients with diabetes mellitus. Diabetes Care 25:213-229, 2002
116. Treatment of hypertension in adults with diabetes. Diabetes Care 25:199-201, 2002
117. Hypertension diagnosis and treatment. Bloomington, IN, Institute for Clinical Systems Improvement (ICSI), 2002
118. Treatment of adults and children with renal failure: standards and audit measures (ed 3). London, UK, Royal College of Physicians of London and the Renal Association, 2002
119. Mooradian AD: Cardiovascular disease in type 2 diabetes mellitus: Current management guidelines. Arch Intern Med 163:33-40, 2003
120. Caring for Australians with renal impairment, CARI, 2003
121. Arauz-Pacheco C, Parrott MA, Raskin P: Treatment of hypertension in adults with diabetes. Diabetes Care 26:S80-S82, 2003 (suppl 1)
122. Primary Care Provider Targets for Chronic Kidney Disease. NIH Publication No. 03-5350, March 2003
123. Cockcroft DW, Gault MH: Prediction of creatinine clearance from serum creatinine. Nephron 16:31-41, 1976
124. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D: A more accurate method to estimate glomerular filtration rate from serum creatinine: A new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med 130:461-470, 1999
125. Levey AS, Greene T, Kusek JW, Beck G: A simplified equation to predict glomerular filtration rate from serum creatinine. J Am Soc Nephrol 11:A0828, 2000 (abstr)
126. Schwartz GJ, Haycock GB, Edelmann CM Jr, Spitzer A: A simple estimate of glomerular filtration rate in children derived from body length and plasma creatinine. Pediatrics 58:259-263, 1976
127. Counahan R, Chantler C, Ghazali S, Kirkwood B, Rose F, Barratt TM: Estimation of glomerular filtration rate from plasma creatinine concentration in children. Arch Dis Child 51:875-878, 1976
127a. Obrador GT, Arora P, Kausz AT, Ruthazer R, Pereira BJ, Levey AS: Level of renal function at the initiation of dialysis in the U.S. end-stage renal disease population. Kidney Int 56:2227-2235, 1999
128. Keane WF, Eknoyan G: Proteinuria, albuminuria, risk, assessment, detection, elimination (PARADE): A position paper of the National Kidney Foundation. Am J Kidney Dis 33:1004-1010, 1999
129. Eknoyan G, Hostetter T, Bakris GL, Hebert L, Levey AS, Parving HH, Steffes MW, Toto R: Proteinuria and other markers of chronic kidney disease: A position statement of the national kidney foundation (NKF) and the national institute of diabetes and digestive and kidney diseases (NIDDK). Am J Kidney Dis 42:617-622, 2003
130. Kinchen KS, Sadler J, Fink N, Brookmeyer R, Klag MJ, Levey AS, Powe NR: The timing of specialist evaluation in chronic kidney disease and mortality. Ann Intern Med 137:479-486, 2002
131. Avorn J, Bohn RL, Levy E, Levin R, Owen WF Jr, Winkelmayer WC, Glynn RJ: Nephrologist care and mortality in patients with chronic renal insufficiency. Arch Intern Med 162:2002-2006, 2002
132. Levinsky NG: Specialist evaluation in chronic kidney disease: too little, too late. Ann Intern Med 137:542-543, 2002
133. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). SHEP Cooperative Research Group. JAMA 265:3255-3264, 1991
134. Dahlof B, Devereux RB, Kjeldsen SE, Julius S, Beevers G, Faire U, Fyhrquist F, Ibsen H, Kristiansson K, Lederballe-Pedersen O, Lindholm LH, Nieminen MS, Omvik P, Oparil S, Wedel H: Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): A randomised trial against atenolol. Lancet 359:995-1003, 2002
135. Guasch A, Parham M, Zayas CF, Campbell O, Nzerue C, Macon E: Contrasting effects of calcium channel blockade versus converting enzyme inhibition on proteinuria in African Americans with non-insulin-dependent diabetes mellitus and nephropathy. J Am Soc Nephrol 8:793-798, 1997
136. Burns GC, Paul SK, Toth IR, Sivak SL: Effect of angiotensin-converting enzyme inhibition in HIV-associated nephropathy. J Am Soc Nephrol 8:1140-1146, 1997
137. Aoki RY, Saad ST: Enalapril reduces the albuminuria of patients with sickle cell disease. Am J Med 98:432-435, 1995
138. Coggins CH, Breyer Lewis J, Caggiula AW, Castaldo LS, Klahr S, Wang SR: Differences between women and men with chronic renal disease. Nephrol Dial Transplant 13:1430-1437, 1998
139. Lewis EJ, Hunsicker LG, Clarke WR, Berl T, Pohl MA, Lewis JB, Ritz E, Atkins RC, Rohde R, Raz I: Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 345:851-860, 2001
140. Jackson TW, Bakris G, Greene T, et al: Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease. Results from the AASK Trial. JAMA 288:2421-2431, 2002
141. Wright JT Jr, Bakris G, Greene T, Agodoa LY, Appel LJ, Charleston J, Cheek D, Douglas-Baltimore JG, Gassman J, Glassock R, Hebert L, Jamerson K, Lewis J, Phillips RA, Toto RD, Middleton JP, Rostand SG: Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial. JAMA 288:2421-2431, 2002
142. Appel L, Robinson K, Guallar E: Utility of Blood Pressure Monitoring of the Clinical Setting. Evidence Report/Technology Assessment No. 63 (Prepared by the Johns Hopkins Evidence-Based Practice Center under Contract No. 290-97-006). AHRQ Publication No. 03-E004. Rockville, MD, Agency for Healthcare Research and Quality, November 2002
143. O’Brien E, Asmar R, Beilin L, Imai Y, Mallion JM, Mancia G, Mengden T, Myers M, Padfield P, Palatini P, Parati G, Pickering T, Redon J, Staessen J, Stergiou G, Verdecchia P: European Society of Hypertension recommendations for conventional, ambulatory and home blood pressure measurement. J Hypertens 21:821-848, 2003
144. Jones DW, Appel LJ, Sheps SG, Roccella EJ, Lenfant C: Measuring blood pressure accurately: New and persistent challenges. JAMA 289:1027-1030, 2003
145. Hospitals for a Healthy Environment. Memorandum of understanding: EPA-AHA Agreement.
146. Pavlik VN, Hyman DJ, Toronjo C: Comparison of automated and mercury column blood pressure measurements in health care settings. J Clin Hypertens 2:81-86, 2000
147. Pickering T: Future developments in ambulatory blood pressure monitoring and self-blood pressure monitoring in clinical practice. Blood Press Monit 7:21-25, 2002
148. Staessen JA, Fagard R, Thijs L, Amery A: A consensus view on the technique of ambulatory blood pressure monitoring. The Fourth International Consensus Conference on 24-Hour Ambulatory Blood Pressure Monitoring. Hypertension 26:912-918, 1995
149. Prisant LM: Ambulatory blood pressure monitoring: Test reproducibility and its implications. Blood Press Monit 3:221-225, 1998
150. Wuhl E, Witte K, Soergel M, Mehls O, Schaefer F, Kirschstein M, Busch C, Danne T, Gellermann J, Holl R, Krull F, Reichert H, Reusz GS, Rascher W: Distribution of 24-h ambulatory blood pressure in children: Normalized reference values and role of body dimensions. J Hypertens 20:1995-2007, 2002
151. White WB: Ambulatory blood pressure as a predictor of target organ disease and outcome in the hypertensive patient. Blood Press Monit 4:181-184, 1999
152. National Heart, Lung, and Blood Institute/American Heart Association Working Meeting on Blood Pressure Measurements: Summary Report
153. Perloff D, Grim C, Flack J, Frohlich ED, Hill M, McDonald M, Morgenstern BZ: Human blood pressure determination by sphygmomanometry. Circulation 88:2460-2470, 1993
154. Staessen JA, Asmar R, De Buyzere M, Imai Y, Parati G, Shimada K, Stergiou G, Redon J, Verdecchia P: Task Force II: Blood pressure measurement and cardiovascular outcome. Blood Press Monit 6:355-370, 2001
155. Konings CJ, Dammers R, Rensma PL, Kooman JP, Hoeks AP, Kornet L, Gladziwa U, van der Sande FM, Leunissen KM: Arterial wall properties in patients with renal failure. Am J Kidney Dis 39:1206-1212, 2002
156. Markandu ND, Whitcher F, Arnold A, Carney C: The mercury sphygmomanometer should be abandoned before it is proscribed. J Hum Hypertens 14:31-36, 2000
157. Vanasse A, Courteau J: [Evaluation of sphygmomanometers used by family physicians practicing outside the hospital environment in Bas-Saint-Laurent]. Can Fam Physician 47:281-286, 2001
158. Mion D, Pierin AM: How accurate are sphygmomanometers? J Hum Hypertens 12:245-248, 1998
159. Knight T, Leech F, Jones A, Walker L, Wickramasinghe R, Angris S, Rolfe P: Sphygmomanometers in use in general practice: An overlooked aspect of quality in patient care. J Hum Hypertens 15:681-684, 2001
160. O’Brien E, Petrie J, Littler WA, de Swiet M, Padfield PD, Dillon MJ, et al: Blood Pressure Measurement: Recommendations of the British Hypertension Society (ed 3). London, UK, BMJ Publishing Group, 1997
161. Association for the Advancement of Medical Instrumentation: American National Standard. Electronic or automated sphygmomanometer. ANSI/AAMi SP 10-1992. Arlington, VA, AAMI, 1992
162. O’Brien E, van Montfrans G, Palatini P, Tochikubo O, Staessen J, Shirasaki O, Lipicky R, Myers M: Task Force I: Methodological aspects of blood pressure measurement. Blood Press Monit 6:313-315, 2001
163. O’Brien E: State of the market for devices for blood pressure measurement. Blood Press Monit 6:281-286, 2001
164. Myers MG: Reporting bias in self-measurement of blood pressure. Blood Press Monit 6:181-183, 2001
165. Mengden T, Hernandez Medina RM, Beltran B, Alvarez E, Kraft K, Vetter H: Reliability of reporting self-measured blood pressure values by hypertensive patients. Am J Hypertens 11:1413-1417, 1998
166. Mazze RS, Shamoon H, Pasmantier R, Lucido D, Murphy J, Hartmann K, Kuykendall V, Lopatin W: Reliability of blood glucose monitoring by patients with diabetes mellitus. Am J Med 77:211-217, 1984
167. Gong H Jr, Simmons MS, Clark VA, Tashkin DP: Metered-dose inhaler usage in subjects with asthma: Comparison of Nebulizer Chronolog and daily diary recordings. J Allergy Clin Immunol 82:5-10, 1988
168. Staessen JA, Beilin L, Parati G, Waeber B, White W: Task force IV: Clinical use of ambulatory blood pressure monitoring. Participants of the 1999 Consensus Conference on Ambulatory Blood Pressure Monitoring. Blood Press Monit 4:319-331, 1999
169. White WB: Clinical utility of ambulatory blood pressure: Perspectives for national insurance coverage. Blood Press Monit 7:27-31, 2002
170. Hoegholm A, Kristensen KS, Bang LE, Nielsen JW: White coat hypertension and target organ involvement: The impact of different cut-off levels on albuminuria and left ventricular mass and geometry. J Hum Hypertens 12:433-439, 1998
171. White WB: Ambulatory blood-pressure monitoring in clinical practice. N Engl J Med 348:2377-2378, 2003
172. Clement DL, De Buyzere ML, De Bacquer DA, de Leeuw PW, Duprez DA, Fagard RH, Gheeraert PJ, Missault LH, Braun JJ, Six RO, Van Der Niepen P, O’Brien E: Prognostic value of ambulatory blood-pressure recordings in patients with treated hypertension. N Engl J Med 348:2407-2415, 2003
173. Pickering TG, Davidson K, Gerin W, Schwartz JE: Masked hypertension. Hypertension 40:795-796, 2002
174. Covic A, Goldsmith DJ, Farmer CK, Cox J, Dallyn P, Sharpstone P, Kingswood JC: How reproducible is diurnal blood pressure rhythm in patients with secondary (renal) hypertension? Rev Med Chir Soc Med Nat Iasi 103:88-93, 1999
175. Staessen JA, O’Brien ET: Development of diagnostic thresholds for automated measurement of blood pressures in adults. Blood Press Monit 4:127-136, 1999
176. Baumgart P, Walger P, Gemen S, von Eiff M, Raidt H, Rahn KH: Blood pressure elevation during the night in chronic renal failure, hemodialysis and after renal transplantation. Nephron 57:293-298, 1991
177. Middeke M, Schrader J: Nocturnal blood pressure in normotensive subjects and those with white coat, primary, and secondary hypertension. BMJ 308:630-632, 1994
178. McGregor DO, Olsson C, Lynn KL: Autonomic dysfunction and ambulatory blood pressure in renal transplant recipients. Transplantation 71:1277-1281, 2001
179. Lurbe E, Redon J, Kesani A, Pascual JM, Tacons J, Alvarez V, Batlle D: Increase in nocturnal blood pressure and progression to microalbuminuria in type 1 diabetes. N Engl J Med 347:797-805, 2002
180. Csiky B, Kovacs T, Wagner L, Vass T, Nagy J: Ambulatory blood pressure monitoring and progression in patients with IgA nephropathy. Nephrol Dial Transplant 14:86-90, 1999
181. Timio M, Venanzi S, Lolli S, Lippi G, Verdura C, Monarca C, Guerrini E: "Non-dipper" hypertensive patients and progressive renal insufficiency: A 3-year longitudinal study. Clin Nephrol 43:382-387, 1995
182. Farmer CK, Goldsmith DJ, Quin JD, Dallyn P, Cox J, Kingswood JC, Sharpstone P: Progression of diabetic nephropathy—Is diurnal blood pressure rhythm as important as absolute blood pressure level? Nephrol Dial Transplant 13:635-639, 1998
183. Nakano S, Fukuda M, Hotta F, Ito T, Ishii T, Kitazawa M, Nishizawa M, Kigoshi T, Uchida K: Reversed circadian blood pressure rhythm is associated with occurrences of both fatal and nonfatal vascular events in NIDDM subjects. Diabetes 47:1501-1506, 1998
184. Tucker B, Fabbian F, Giles M, Thuraisingham RC, Raine AE, Baker LR: Left ventricular hypertrophy and ambulatory blood pressure monitoring in chronic renal failure. Nephrol Dial Transplant 12:724-728, 1997
185. Palatini P, Mormino P, Santonastaso M, Mos L, Dal Follo M, Zanata G, Pessina AC: Target-organ damage in stage I hypertensive subjects with white coat and sustained hypertension: Results from the HARVEST study. Hypertension 31:57-63, 1998
186. Cuspidi C, Lonati L, Sampieri L, Michev I, Macca G, Rocanova JI, Salerno M, Fusi V, Leonetti G, Zanchetti A: Prevalence of target organ damage in treated hypertensive patients: Different impact of clinic and ambulatory blood pressure control. J Hypertens 18:803-809, 2000
187. Deal JE, Snell MF, Barratt TM, Dillon MJ: Renovascular disease in childhood. J Pediatr 121:378-384, 1992
188. Bendel-Stenzel M, Najarian JS, Sinaiko AR: Renal artery stenosis in infants: Long-term medical treatment before surgery. Pediatr Nephrol 10:147-151, 1996
189. Plumer LB, Mendoza SA, Kaplan GW: Hypertension in infancy: The case for aggressive management. J Urol 113:555-557, 1975
190. Adelman RD, Merten D, Vogel J, Goetzman BW, Wennberg RP: Nonsurgical management of renovascular hypertension in the neonate. Pediatrics 62:71-76, 1978
191. Sinaiko AR, Mirkin BL, Hendrick DA, Green TP, O’Dea RF: Antihypertensive effect and elimination kinetics of captopril in hypertensive children with renal disease. J Pediatr 103:799-805, 1983
192. van de Ven PJ, Beutler JJ, Kaatee R, Beek FJ, Mali WP, Koomans HA: Angiotensin converting enzyme inhibitor-induced renal dysfunction in atherosclerotic renovascular disease. Kidney Int 53:986-993, 1998
193. Bakris GL, Weir MR: Angiotensin-converting enzyme inhibitor-associated elevations in serum creatinine: Is this a cause for concern? Arch Intern Med 160:685-693, 2000
194. Short-term effects of protein intake, blood pressure, and antihypertensive therapy on glomerular filtration rate in the Modification of Diet in Renal Disease Study. J Am Soc Nephrol 7:2097-2109, 1996
195. Krijnen P, van Jaarsveld BC, Steyerberg EW, Man in ’t Veld AJ, Schalekamp MA, Habbema JD: A clinical prediction rule for renal artery stenosis. Ann Intern Med 129:705-711, 1998
196. Wilcox CS: Screening for renal artery stenosis: Are scans more accurate than clinical criteria? Ann Intern Med 129:738-740, 1998
197. Elliott WJ, Martin WB, Murphy MB: Comparison of two noninvasive screening tests for renovascular hypertension. Arch Intern Med 153:755-764, 1993
198. Blaufox MD, Middleton ML, Bongiovanni J, Davis BR: Cost efficacy of the diagnosis and therapy of renovascular hypertension. J Nucl Med 37:171-177, 1996
199. Vasbinder GB, Nelemans PJ, Kessels AG, Kroon AA, de Leeuw PW, van Engelshoven JM: Diagnostic tests for renal artery stenosis in patients suspected of having renovascular hypertension: A meta-analysis. Ann Intern Med 135:401-411, 2001
200. Radermacher J, Chavan A, Bleck J, Vitzthum A, Stoess B, Gebel MJ, Galanski M, Koch KM, Haller H: Use of Doppler ultrasonography to predict the outcome of therapy for renal-artery stenosis. N Engl J Med 344:410-417, 2001
201. Setaro JF, Saddler MC, Chen CC, Hoffer PB, Roer DA, Markowitz DM, Meier GH, Gusberg RJ, Black HR: Simplified captopril renography in diagnosis and treatment of renal artery stenosis. Hypertension 18:289-298, 1991
202. Dondi M, Fanti S, De Fabritiis A, Zuccala A, Gaggi R, Mirelli M, Stella A, Marengo M, Losinno F, Monetti N: Prognostic value of captopril renal scintigraphy in renovascular hypertension. J Nucl Med 33:2040-2044, 1992
203. Pedersen EB: Angiotensin-converting enzyme inhibitor renography. Pathophysiological, diagnostic and therapeutic aspects in renal artery stenosis. Nephrol Dial Transplant 9:482-492, 1994
204. Franklin SS, Smith RD: Comparison of effects of enalapril plus hydrochlorothiazide versus standard triple therapy on renal function in renovascular hypertension. Am J Med 79:14-23, 1985
205. Jackson B, Murphy BF, Johnston CI, Kincaid-Smith P, Whitworth JA: Renovascular hypertension: Treatment with the oral angiotensin-converting enzyme inhibitor enalapril. Am J Nephrol 6:182-186, 1986
206. Jackson B, McGrath BP, Matthews PG, Wong C, Johnston CI: Differential renal function during angiotensin converting enzyme inhibition in renovascular hypertension. Hypertension 8:650-654, 1986
207. Hodsman GP, Brown JJ, Cumming AM, Davies DL, East BW, Lever AF, Morton JJ, Murray GD, Robertson JI: Enalapril in treatment of hypertension with renal artery stenosis. Changes in blood pressure, renin, angiotensin I and II, renal function, and body composition. Am J Med 77:52-60, 1984
208. Greminger P, Luscher TF, Zuber J, Kuhlmann U, Schneider E, Siegenthaler W, Largiader F, Vetter W: Surgery, transluminal dilatation and medical therapy in the management of renovascular hypertension. Nephron 44:36-39, 1986 (suppl 1)
209. Chabova V, Schirger A, Stanson AW, McKusick MA, Textor SC: Outcomes of atherosclerotic renal artery stenosis managed without revascularization. Mayo Clin Proc 75:437-444, 2000
210. Losito A, Gaburri M, Errico R, Parente B, Cao PG: Survival of patients with renovascular disease and ACE inhibition. Clin Nephrol 52:339-343, 1999
211. van Jaarsveld BC, Krijnen P, Pieterman H, Derkx FH, Deinum J, Postma CT, Dees A, Woittiez AJ, Bartelink AK, Man in ’t Veld AJ, Schalekamp MA: The effect of balloon angioplasty on hypertension in atherosclerotic renal-artery stenosis. Dutch Renal Artery Stenosis Intervention Cooperative Study Group. N Engl J Med 342:1007-1014, 2000
212. Plouin PF, Chatellier G, Darne B, Raynaud A: Blood pressure outcome of angioplasty in atherosclerotic renal artery stenosis: A randomized trial. Essai Multicentrique Medicaments vs Angioplastie (EMMA) Study Group. Hypertension 31:823-829, 1998
213. Uzzo RG, Novick AC, Goormastic M, Mascha E, Pohl M: Medical versus surgical management of atherosclerotic renal artery stenosis. Transplant Proc 34:723-725, 2002
214. Clark NM, Becker MH: Theoretical models and strategies for improving adherence and disease management, in SAS, EBS, JKO, WLM (eds): Handbook of Health Behavior Change (ed 2). New York, NY, Springer, 1998, pp 5-32
215. Burt VL, Whelton P, Roccella EJ, Brown C, Cutler JA, Higgins M, Horan MJ, Labarthe D: Prevalence of hypertension in the US adult population. Results from the Third National Health and Nutrition Examination Survey, 1988-1991. Hypertension 25:305-313, 1995
216. Mallion JM, Genes N, Vaur L, Clerson P, Vaisse B, Bobrie G, Chatellier G: Blood pressure levels, risk factors and antihypertensive treatments: Lessons from the SHEAF study. J Hum Hypertens 15:841-848, 2001
217. Burt VL, Cutler JA, Higgins M, Horan MJ, Labarthe D, Whelton P, Brown C, Roccella EJ: Trends in the prevalence, awareness, treatment, and control of hypertension in the adult US population. Data from the health examination surveys, 1960 to 1991. Hypertension 26:60-69, 1995
218. Knight EL, Bohn RL, Wang PS, Glynn RJ, Mogun H, Avorn J: Predictors of uncontrolled hypertension in ambulatory patients. Hypertension 38:809-814, 2001
219. Neutel JM: The use of combination drug therapy in the treatment of hypertension. Prog Cardiovasc Nurs 17:81-88, 2002
220. Gavras HP: Issues in hypertension: Drug tolerability and special populations. Am J Hypertens 14:231S-236S, 2001
221. Freis ED: Improving treatment effectiveness in hypertension. Arch Intern Med 159:2517-2521, 1999
222. Sharkness CM, Snow DA: The patient’s view of hypertension and compliance. Am J Prev Med 8:141-146, 1992
223. Feldman R, Bacher M, Campbell N, Drover A, Chockalingam A: Adherence to pharmacologic management of hypertension. Can J Public Health 89:I16-18, 1998
224. Tomlinson B: Optimal dosage of ACE inhibitors in older patients. Drugs Aging 9:262-273, 1996
225. Alderman MH, Madhavan S, Cohen H: Antihypertensive drug therapy. The effect of JNC criteria on prescribing patterns and patient status through the first year. Am J Hypertens 9:413-418, 1996
226. Flack JM, Novikov SV, Ferrario CM: Benefits of adherence to anti-hypertensive drug therapy. Eur Heart J 17:16-20, 1996 (suppl A)
227. Cheng JW, Kalis MM, Feifer S: Patient-reported adherence to guidelines of the Sixth Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Pharmacotherapy 21:828-841, 2001
228. Degli Esposti E, Sturani A, Degli Esposti L, Macini PL, Falasca P, Valpiani G, Buda S: Pharmacoutilization of antihypertensive drugs: A model of analysis. Int J Clin Pharmacol Ther 39:251-258, 2001
229. Whelton PK, Appel LJ, Espeland MA, Applegate WB, Ettinger WH Jr, Kostis JB, Kumanyika S, Lacy CR, Johnson KC, Folmar S, Cutler JA: Sodium reduction and weight loss in the treatment of hypertension in older persons: A randomized controlled trial of nonpharmacologic interventions in the elderly (TONE). TONE Collaborative Research Group. JAMA 279:839-846, 1998
230. Appel LJ, Moore TJ, Obarzanek E, Vollmer WM, Svetkey LP, Sacks FM, Bray GA, Vogt TM, Cutler JA, Windhauser MM, Lin PH, Karanja N: A clinical trial of the effects of dietary patterns on blood pressure. DASH Collaborative Research Group. N Engl J Med 336:1117-1124, 1997
231. Liebson PR, Grandits GA, Dianzumba S, Prineas RJ, Grimm RH Jr, Neaton JD, Stamler J: Comparison of five antihypertensive monotherapies and placebo for change in left ventricular mass in patients receiving nutritional-hygienic therapy in the Treatment of Mild Hypertension Study (TOMHS). Circulation 91:698-706, 1995
232. Stevens VJ, Corrigan SA, Obarzanek E, Bernauer E, Cook NR, Hebert P, Mattfeldt-Beman M, Oberman A, Sugars C, Dalcin AT, et al: Weight loss intervention in phase 1 of the Trials of Hypertension Prevention. The TOHP Collaborative Research Group. Arch Intern Med 153:849-858, 1993
233. Elmer PJ, Grimm RH Jr, Flack J, Laing B: Dietary sodium reduction for hypertension prevention and treatment. Hypertension 17:I182-189, 1991
234. Midgley JP, Matthew AG, Greenwood CM, Logan AG: Effect of reduced dietary sodium on blood pressure: A meta-analysis of randomized controlled trials. JAMA 275:1590-1597, 1996
235. Bodenheimer T, Lorig K, Holman H, Grumbach K: Patient self-management of chronic disease in primary care. JAMA 288:2469-2475, 2002
236. Lorig KR, Sobel DS, Ritter PL, Laurent D, Hobbs M: Effect of a self-management program on patients with chronic disease. Eff Clin Pract 4:256-262, 2001
237. Lorig KR, Ritter P, Stewart AL, Sobel DS, Brown BW Jr, Bandura A, Gonzalez VM, Laurent DD, Holman HR: Chronic disease self-management program: 2-year health status and health care utilization outcomes. Med Care 39:1217-1223, 2001
238. McCann BS, Bovberg VE: Promoting dietary change, in SAS, EBS, JKO, WLM (eds): Handbook of Health Behavior Change (ed 2). New York, NY, Springer, 1998, pp 166-168
239. Mulrow CD, Chiquette E, Angel L, Cornell J, Summerbell C, Anagnostelis B, Brand M, Grimm R: Dieting to reduce body weight for controlling hypertension in adults. (Cochrane Review). The Cochrane Library, Issue 4, 2002
240. Murdaugh CL: Problems with Adherence in the Elderly, in SAS, EBS, JKO, WLM (eds): Handbook of Health Behavior Change (ed 2). New York, NY, Springer, 1998, pp 357-376
241. Salas M, In’t Veld BA, van der Linden PD, Hofman A, Breteler M, Stricker BH: Impaired cognitive function and compliance with antihypertensive drugs in elderly: The Rotterdam Study. Clin Pharmacol Ther 70:561-566, 2001
242. Haynes RB, McDonald H, Garg AX, Montague P: Interventions for helping patients to follow prescriptions for medications (Cochrane Review). The Cochrane Library, Issue 4, 2002
243. Friedman RH, Kazis LE, Jette A, Smith MB, Stollerman J, Torgerson J, Carey K: A telecommunications system for monitoring and counseling patients with hypertension. Impact on medication adherence and blood pressure control. Am J Hypertens 9:285-292, 1996
244. Becker LA, Glanz K, Sobel E, Mossey J, Zinn SL, Knott KA: A randomized trial of special packaging of antihypertensive medications. J Fam Pract 22:357-361, 1986
245. Baird MG, Bentley-Taylor MM, Carruthers SG, Dawson KG, Laplante LE, Larochelle P, MacCannell KL, Marquez-Julio A, Silverberg LR, Talbot P: A study of efficacy, tolerance and compliance of once-daily versus twice-daily metoprolol (Betaloc) in hypertension. Betaloc Compliance Canadian Cooperative Study Group. Clin Invest Med 7:95-102, 1984
246. Logan AG, Milne BJ, Achber C, Campbell WP, Haynes RB: Work-site treatment of hypertension by specially trained nurses. A controlled trial. Lancet 2:1175-1178, 1979
247. Johnson AL, Taylor DW, Sackett DL, Dunnett CW, Shimizu AG: Self-recording of blood pressure in the management of hypertension. Can Med Assoc J 119:1034-1039, 1978
248. Haynes RB, Sackett DL, Gibson ES, Taylor DW, Hackett BC, Roberts RS, Johnson AL: Improvement of medication compliance in uncontrolled hypertension. Lancet 1:1265-1268, 1976
249. Sackett DL, Haynes RB, Gibson ES, Hackett BC, Taylor DW, Roberts RS, Johnson AL: Randomised clinical trial of strategies for improving medication compliance in primary hypertension. Lancet 1:1205-1207, 1975
249a. Beder J, Johnstone S, Callahan MB, Le Sage L: Effectiveness of a social work psychoeducational program in improving adherence behavior associated with risk of CKD in ESRD patients. J Nephrol Social Work 22:12-22, 2003
250. Monane M, Bohn RL, Gurwitz JH, Glynn RJ, Levin R, Avorn J: The effects of initial drug choice and comorbidity on antihypertensive therapy compliance: Results from a population-based study in the elderly. Am J Hypertens 10:697-704, 1997
251. Fogari R, Zoppi A: Effects of antihypertensive therapy on sexual activity in hypertensive men. Curr Hypertens Rep 4:202-210, 2002
252. Svensson S, Kjellgren KI, Ahlner J, Saljo R: Reasons for adherence with antihypertensive medication. Int J Cardiol 76:157-163, 2000
253. Schillinger D, Piette J, Grumbach K, Wang F, Wilson C, Daher C, Leong-Grotz K, Castro C, Bindman AB: Closing the loop: physician communication with diabetic patients who have low health literacy. Arch Intern Med 163:83-90, 2003
254. Wagner L: Hypertension in African-American males. Clin Excell Nurse Pract 2:225-231, 1998
255. Wilson RP, Freeman A, Kazda MJ, Andrews TC, Berry L, Vaeth PA, Victor RG: Lay beliefs about high blood pressure in a low- to middle-income urban African-American community: An opportunity for improving hypertension control. Am J Med 112:26-30, 2002
256. Sudano JJ Jr, Baker DW: Antihypertensive medication use in Hispanic adults: A comparison with black adults and white adults. Med Care 39:575-587, 2001
257. Kim C, Kwok YS: Navajo use of native healers. Arch Intern Med 158:2245-2249, 1998
258. Resnicow K, Braithwaite RL: Cultural sensitivity in public health, in Braithwaite RL, Taylor SE (eds): Health Issues in the Black Community. San Francisco, CA, Jossey-Bass Publishers, 2001, pp 516-542
259. Enlund H, Jokisalo E, Wallenius S, Korhonen M: Patient-perceived problems, compliance, and the outcome of hypertension treatment. Pharm World Sci 23:60-64, 2001
260. Ambrosioni E, Leonetti G, Pessina AC, Rappelli A, Trimarco B, Zanchetti A: Patterns of hypertension management in Italy: Results of a pharmacoepidemiological survey on antihypertensive therapy. Scientific Committee of the Italian Pharmacoepidemiological Survey on Antihypertensive Therapy. J Hypertens 18:1691-1699, 2000
261. Degli Esposti E, Sturani A, Di Martino M, Falasca P, Novi MV, Baio G, Buda S, Volpe M: Long-term persistence with antihypertensive drugs in new patients. J Hum Hypertens 16:439-444, 2002
262. Marentette MA, Gerth WC, Billings DK, Zarnke KB: Antihypertensive persistence and drug class. Can J Cardiol 18:649-656, 2002
263. Ruzicka M, Leenen FH: Monotherapy versus combination therapy as first line treatment of uncomplicated arterial hypertension. Drugs 61:943-954, 2001
264. Sica DA: Rationale for fixed-dose combinations in the treatment of hypertension: The cycle repeats. Drugs 62:443-462, 2002
265. Cohen JS: Adverse drug effects, compliance, and initial doses of antihypertensive drugs recommended by the Joint National Committee vs the Physicians’ Desk Reference. Arch Intern Med 161:880-885, 2001
266. Dezji CM: A retrospective study of persistence with single-pill combination therapy vs. concurrent two-pill therapy in patients with hypertension. Managed Care 9:206, 2000 (suppl 9)
267. Andrejak M, Genes N, Vaur L, Poncelet P, Clerson P, Carre A: Electronic pill-boxes in the evaluation of antihypertensive treatment compliance: Comparison of once daily versus twice daily regimen. Am J Hypertens 13:184-190, 2000
268. Iskedjian M, Einarson TR, MacKeigan LD, Shear N, Addis A, Mittmann N, Ilersich AL: Relationship between daily dose frequency and adherence to antihypertensive pharmacotherapy: evidence from a meta-analysis. Clin Ther 24:302-316, 2002
269. Mitchell J, Mathews HF, Hunt LM, Cobb KH, Watson RW: Mismanaging prescription medications among rural elders: The effects of socioeconomic status, health status, and medication profile indicators. Gerontologist 41:348-356, 2001
270. Ahluwalia JS, McNagny SE, Rask KJ: Correlates of controlled hypertension in indigent, inner-city hypertensive patients. J Gen Intern Med 12:7-14, 1997
271. Wang PS, Bohn RL, Knight E, Glynn RJ, Mogun H, Avorn J: Noncompliance with antihypertensive medications: The impact of depressive symptoms and psychosocial factors. J Gen Intern Med 17:504-511, 2002
272. Irwin CE Jr, Millstein SG, Ellen JM: Appointment-keeping behavior in adolescents: Factors associated with follow-up appointment-keeping. Pediatrics 92:20-23, 1993
273. McClure RJ, Newell SJ, Edwards S: Patient characteristics affecting attendance at general outpatient clinics. Arch Dis Child 74:121-125, 1996
274. McPherson ML, Lairson DR, Smith EO, Brody BA, Jefferson LS: Noncompliance with medical follow-up after pediatric intensive care. Pediatrics 109:e94, 2002
275. Tershakovec AM, Kuppler K: Ethnicity, insurance type, and follow-up in a pediatric weight management program. Obes Res 11:17-20, 2003
275a. Williams M, Baker D, Parker R, Nurss JR: Relationship of functional health literacy to patients’ knowledge of their chronic disease: A study of patients with hypertension and diabetes. Arch Intern Med 158:166-172, 1998
275b. Fouad MN, Kiefe CI, Bartolucci AA, Burst NM, Ulene V, Harvey MR: A hypertension control program tailored to unskilled and minority workers. Ethnicity Dis 7:191-199, 1997
276. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 285:2486-2497, 2001
277. American Diabetes Association: Clinical Practice Recommendations 2000. Diabetes Care 23:S1-S116, 2000 (suppl 1)
278. Clinical Practice Guidelines for Nutrition in Chronic Renal Failure. K/DOQI, National Kidney Foundation. Am J Kidney Dis 35:S1-S140, 2000 (suppl 3)
279. Stampfer MJ, Hu FB, Manson JE, Rimm EB, Willett WC: Primary prevention of coronary heart disease in women through diet and lifestyle. N Engl J Med 343:16-22, 2000
280. Hu FB, Willett WC: Optimal diets for prevention of coronary heart disease. JAMA 288:2569-2578, 2002
281. Sacks FM, Svetkey LP, Vollmer WM, Appel LJ, Bray GA, Harsha D, Obarzanek E, Conlin PR, Miller ER 3rd, Simons-Morton DG, Karanja N, Lin PH: Effects on blood pressure of reduced dietary sodium and the Dietary Approaches to Stop Hypertension (DASH) diet. DASH-Sodium Collaborative Research Group. N Engl J Med 344:3-10, 2001
281a. Conlin PR, Chow DC, Miller ER III, Svetky LP, Lin P-H, Harsha DW, Moore TJ, Sacks FM, Appel LJ: The effect of dietary patterns on blood pressure control in hypertensive patients: Results from the Dietary Approaches to Stop Hypertension (DASH) Trial. Am J Hypertens 13:949-955, 2000
281b. Johnson RJ, Herrera-Acosta J, Schreiner GF, Rodriguez-Iturbe B: Mechanisms of disease: Subtle acquired renal injury as a mechanism of salt-sensitive hypertension. N Engl J Med 346:913-923, 2002
282. Johnson RJ, Herrera-Acosta J, Schreiner GF, Rodriguez-Iturbe B: Subtle acquired renal injury as a mechanism of salt-sensitive hypertension. N Engl J Med 346:913-923, 2002
283. Food and Nutrition Board, Institute of Medicine: Dietary reference intakes for energy, carbohydrate, fiber, fat, fatty acids, cholesterol, protein and amino acids. Washington, DC, National Academy Press, 2002
283a. Food and Nutrition Board, Institute of Medicine: Dietary reference intakes for calcium, phosphorus, magnesium, vitamin D, and fluoride. Washington, DC, National Academy Press, 1997
284. Levey AS, Greene T, Beck GJ, Caggiula AW, Kusek JW, Hunsicker LG, Klahr S: Dietary protein restriction and the progression of chronic renal disease: What have all of the results of the MDRD study shown? Modification of Diet in Renal Disease Study group. J Am Soc Nephrol 10:2426-2439, 1999
284a. Dietary Reference Intakes for Calcium, Phosphorus, Magnesium, Vitamin D, and Fluoride. Washington, DC, National Academies, 1997
285. Coburn JW, Elangovan L: Prevention of metabolic bone disease in the pre-end-stage renal disease setting. J Am Soc Nephrol 9:S71-S77, 1998
286. Dwyer JT, Cunniff PJ, Maroni BJ, Kopple JD, Burrowes JD, Powers SN, Cockram DB, Chumlea WC, Kusek JW, Makoff R, Goldstein DJ, Paranandi L: The hemodialysis pilot study: Nutrition program and participant characteristics at baseline. The HEMO Study Group. J Ren Nutr 8:11-20, 1998
287. Adequacy of dialysis and nutrition in continuous peritoneal dialysis: Association with clinical outcomes. Canada-USA (CANUSA) Peritoneal Dialysis Study Group. J Am Soc Nephrol 7:198-207, 1996
288. Caggiula AW, Bosch JP, Habwe VQ, Kusek J, McLeroy S, Milas NC, Scherch L, Stollar C: Dietary compliance patterns in the Modification of Diet in Renal Disease (MDRD) Study, Phase III. J Am Soc Nephrol 1:288, 1990 (abstr)
289. Centers for Disease Control and Prevention, National Center for Health Statistics. National Health and Nutrition Examination Survey (NHANES III), 1988-1991, Data Computed for the National Heart, Lung, and Blood Institute. Atlanta, GA, Centers for Disease Control and Prevention, 1988-1991
290. Ernst ND, Sempos CT, Briefel RR, Clark MB: Consistency between US dietary fat intake and serum total cholesterol concentrations: The National Health and Nutrition Examination Surveys. Am J Clin Nutr 66:965S-972S, 1997
291. K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Kidney Disease Outcome Quality Initiative. Am J Kidney Dis 42:S1-S201, 2003 (suppl 3)
291a. Levey AS, Beto JA, Coronado BE, Eknoyan G, Foley RN, Kasiske BL, Klag MJ, Mailloux LU, Manske CL, Meyer KB, Parfrey PS, Pfeffer MA, Wenger NK, Wilson PW, Wright JT Jr: Controlling the epidemic of cardiovascular disease in chronic renal disease: What do we know? What do we need to learn? Where do we go from here? Natiional Kidney Foundation Task Force on Cardiovascular Disease. Am J Kidney Dis 32:853-906, 1998
291b. K/DOQI Clinical Practice Guidelines for Managing Dyslipidemias in Chronic Kidney Disease. Am J Kidney Dis 41:S1-S92, 2003 (suppl 3)
292. Rahman M, Cutler J, Davis B, Pressel S, Whelton P: Cardiovascular disease (CVD) outcomes in hypertensive patients with impaired renal function. Am J Kidney Dis 41:A31, 2003
293. Rahman M, Cutler J, Davis B, Pressel S, Whelton P: Renal outcomes in hypertensive patients with impaired renal function. Am J Kidney Dis 41:A6, 2003
294. Basic guidelines for diabetes care. California Department of Health Services, Diabetes Control Program, 2002
295. Type 2 diabetes practice guidelines. Staged diabetes management: A systematic approach., in, Minneapolis, MN, Matrex International Diabetes Center, 2000
296. Hypertension. Singapore, Singapore Ministry of Health, 2000
297. Stable coronary artery disease. Bloomington, MN, Institute for Clinical Systems Improvement (ICSI), 2002
298. Prevention of coronary heart disease in clinical practice. Recommendations of the Second Joint Task Force of European and Other Societies on Coronary Prevention. Eur Heart J 19:1434-1503, 1998
299. Gibbons RJ, Chatterjee K, Daley J, Douglas JS, Fihn SD, Gardin JM, Grunwald MA, Levy D, Lytle BW, O’Rourke RA, Schafer WP, Williams SV, Ritchie JL, Cheitlin MD, Eagle KA, Gardner TJ, Garson A Jr, Russell RO, Ryan TJ, Smith SC Jr: ACC/AHA/ACP-ASIM guidelines for the management of patients with chronic stable angina: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Management of Patients With Chronic Stable Angina). J Am Coll Cardiol 33:2092-2197, 1999
300. Hunt SA, Baker DW, Chin MH, Cinquegrani MP, Feldman AM, Francis GS, Ganiats TG, Goldstein S, Gregoratos G, Jessup ML, Noble RJ, Packer M, Silver MA, Stevenson LW, Gibbons RJ, Antman EM, Alpert JS, Faxon DP, Fuster V, Jacobs AK, Hiratzka LF, Russell RO, Smith SC Jr: ACC/AHA guidelines for the evaluation and management of chronic heart failure in the adult: Executive summary. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to revise the 1995 Guidelines for the Evaluation and Management of Heart Failure). J Am Coll Cardiol 38:2101-2113, 2001
301. Appel LJ: The verdict from ALLHAT—Thiazide diuretics are the preferred initial therapy for hypertension. JAMA 288:3039-3042, 2002
302. Rahman M, Brown C, Coresh J, Eckfeldr J, Jelley M, Kopyt N, Levey AS, Pressel S, Reisin E, Wentworth C, Davis B, Group ACR: Baseline characteristics of ALLHAT participants with impaired renal function: Association with coexistent cardiovascular disease. Am J Hypertens 15:175A, 2002
303. Holland OB, Gomez-Sanchez CE, Kuhnert LV, Poindexter C, Pak CY: Antihypertensive comparison of furosemide with hydrochlorothiazide for black patients. Arch Intern Med 139:1015-1021, 1979
304. Ram CV, Garrett BN, Kaplan NM: Moderate sodium restriction and various diuretics in the treatment of hypertension. Arch Intern Med 141:1015-1019, 1981
305. Reubi FC, Cottier PT: Effect of reduced glomerular filtration rate on responsiveness to chlorothiazide and mercurial diuretics. Circulation 23:200, 1961
306. Paton RR, Kane RE: Long-term diuretic therapy with metolazone of renal failure and the nephrotic syndrome. J Clin Pharmacol 17:243-251, 1977
307. Rajagopalan S, Pitt B: Aldosterone antagonists in the treatment of hypertension and target organ damage. Curr Hypertens Rep 3:240-248, 2001
308. Pollare T, Lithell H, Morlin C, Prantare H, Hvarfner A, Ljunghall S: Metabolic effects of diltiazem and atenolol: Results from a randomized, double-blind study with parallel groups. J Hypertens 7:551-559, 1989
309. Psaty BM, Smith NL, Siscovick DS, Koepsell TD, Weiss NS, Heckbert SR, Lemaitre RN, Wagner EH, Furberg CD: Health outcomes associated with antihypertensive therapies used as first-line agents. A systematic review and meta-analysis. JAMA 277:739-745, 1997
310. MRC trial of treatment of mild hypertension: Principal results. Medical Research Council Working Party. Br Med J (Clin Res Ed) 291:97-104, 1985
311. Hjalmarson A, Goldstein S, Fagerberg B, Wedel H, Waagstein F, Kjekshus J, Wikstrand J, El Allaf D, Vitovec J, Aldershvile J, Halinen M, Dietz R, Neuhaus KL, Janosi A, Thorgeirsson G, Dunselman PH, Gullestad L, Kuch J, Herlitz J, Rickenbacher P, Ball S, Gottlieb S, Deedwania P: Effects of controlled-release metoprolol on total mortality, hospitalizations, and well-being in patients with heart failure: The Metoprolol CR/XL Randomized Intervention Trial in congestive heart failure (MERIT-HF). MERIT-HF Study Group. JAMA 283:1295-1302, 2000
312. Moser M, Frishman W: Results of therapy with carvedilol, a beta-blocker vasodilator with antioxidant properties, in hypertensive patients. Am J Hypertens 11:15S-22S, 1998
313. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): A randomised trial. Lancet 353:9-13, 1999
314. 1999 World Health Organization-International Society of Hypertension Guidelines for the Management of Hypertension. Guidelines Subcommittee. J Hypertens 17:151-183, 1999
315. Kendall MJ, Lynch KP, Hjalmarson A, Kjekshus J: Beta-blockers and sudden cardiac death. Ann Intern Med 123:358-367, 1995
316. Kaplan NM, Gifford RW Jr: Choice of initial therapy for hypertension. JAMA 275:1577-1580, 1996
317. Radack K, Deck C: Beta-adrenergic blocker therapy does not worsen intermittent claudication in subjects with peripheral arterial disease. A meta-analysis of randomized controlled trials. Arch Intern Med 151:1769-1776, 1991
317a. Nowicki M, Miszczak-Kuban J: Nonselective beta-adrenergic blockade augments fasting hyperkalemia in hemodialysis patients. Nephron 91:222-227, 2002
318. Blaufarb I, Pfeifer TM, Frishman WH: beta-blockers. Drug interactions of clinical significance. Drug Saf 13:359-370, 1995
319. Lalka D, Griffith RK, Cronenberger CL: The hepatic first-pass metabolism of problematic drugs. J Clin Pharmacol 33:657-669, 1993
320. Wood AJ, Feely J: Pharmacokinetic drug interactions with propranolol. Clin Pharmacokinet 8:253-262, 1983
321. Flockhart DA, Tanus-Santos JE: Implications of cytochrome P450 interactions when prescribing medication for hypertension. Arch Intern Med 162:405-412, 2002
322. Miller RR, Olson HG, Amsterdam EA, Mason DT: Propranolol-withdrawal rebound phenomenon. Exacerbation of coronary events after abrupt cessation of antianginal therapy. N Engl J Med 293:416-418, 1975
323. Rangno RE, Nattel S, Lutterodt A: Prevention of propranolol withdrawal mechanism by prolonged small dose propranolol schedule. Am J Cardiol 49:828-833, 1982
324. Psaty BM, Koepsell TD, Wagner EH, LoGerfo JP, Inui TS: The relative risk of incident coronary heart disease associated with recently stopping the use of beta-blockers. JAMA 263:1653-1657, 1990
325. Houston MC: Abrupt cessation of treatment in hypertension: Consideration of clinical features, mechanisms, prevention and management of the discontinuation syndrome. Am Heart J 102:415-430, 1981
326. Schoolwerth AC, Sica DA, Ballermann BJ, Wilcox CS: Renal considerations in angiotensin converting enzyme inhibitor therapy: A statement for healthcare professionals from the Council on the Kidney in Cardiovascular Disease and the Council for High Blood Pressure Research of the American Heart Association. Circulation 104:1985-1991, 2001
327. Viberti G, Mogensen CE, Groop LC, Pauls JF: Effect of captopril on progression to clinical proteinuria in patients with insulin-dependent diabetes mellitus and microalbuminuria. European Microalbuminuria Captopril Study Group. JAMA 271:275-279, 1994
328. Captopril reduces the risk of nephropathy in IDDM patients with microalbuminuria. The Microalbuminuria Captopril Study Group. Diabetologia 39:587-593, 1996
329. Lewis EJ, Hunsicker LG, Bain RP, Rohde RD: The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. N Engl J Med 329:1456-1462, 1993 (erratum 330:152, 1993)
330. Hebert LA, Bain RP, Verme D, Cattran D, Whittier FC, Tolchin N, Rohde RD, Lewis EJ: Remission of nephrotic range proteinuria in type I diabetes. Collaborative Study Group. Kidney Int 46:1688-1693, 1994
331. Wilmer WA, Hebert LA, Lewis EJ, Rohde RD, Whittier F, Cattran D, Levey AS, Lewis JB, Spitalewitz S, Blumenthal S, Bain RP: Remission of nephrotic syndrome in type 1 diabetes: Long-term follow-up of patients in the Captopril Study. Am J Kidney Dis 34:308-314, 1999
332. Hovind P, Rossing P, Tarnow L, Smidt UM, Parving HH: Remission and regression in the nephropathy of type 1 diabetes when blood pressure is controlled aggressively. Kidney Int 60:277-283, 2001
333. Ravid M, Savin H, Jutrin I, Bental T, Katz B, Lishner M: Long-term stabilizing effect of angiotensin-converting enzyme inhibition on plasma creatinine and on proteinuria in normotensive type II diabetic patients. Ann Intern Med 118:577-581, 1993
334. Lebovitz HE, Wiegmann TB, Cnaan A, Shahinfar S, Sica DA, Broadstone V, Schwartz SL, Mengel MC, Segal R, Versaggi JA, et al: Renal protective effects of enalapril in hypertensive NIDDM: role of baseline albuminuria. Kidney Int Suppl 45:S150-S155, 1994
335. Chan JC, Ko GT, Leung DH, Cheung RC, Cheung MY, So WY, Swaminathan R, Nicholls MG, Critchley JA, Cockram CS: Long-term effects of angiotensin-converting enzyme inhibition and metabolic control in hypertensive type 2 diabetic patients. Kidney Int 57:590-600, 2000
336. Nielsen FS, Rossing P, Gall MA, Skott P, Smidt UM, Parving HH: Impact of lisinopril and atenolol on kidney function in hypertensive NIDDM subjects with diabetic nephropathy. Diabetes 43:1108-1113, 1994
337. Bakris GL, Copley JB, Vicknair N, Sadler R, Leurgans S: Calcium channel blockers versus other antihypertensive therapies on progression of NIDDM associated nephropathy. Kidney Int 50:1641-1650, 1996
338. Brenner BM, Cooper ME, de Zeeuw D, Keane WF, Mitch WE, Parving HH, Remuzzi G, Snapinn SM, Zhang Z, Shahinfar S, Renaal SI: Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 345:861-869, 2001
339. Parving HH, Lehnert H, Brochner-Mortensen J, Gomis R, Andersen S, Arner P: Type IiPw: The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 345:870-878, 2001
340. Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). The CONSENSUS Trial Study Group. N Engl J Med 316:1429-1435, 1987
341. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. The SOLVD Investigators. N Engl J Med 325:293-302, 1991
342. Cohn JN, Johnson G, Ziesche S, Cobb F, Francis G, Tristani F, Smith R, Dunkman WB, Loeb H, Wong M, et al: A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure. N Engl J Med 325:303-310, 1991
343. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. The SOLVD Investigattors. N Engl J Med 327:685-691, 1992
344. Pfeffer MA, Braunwald E, Moye LA, Basta L, Brown EJ Jr, Cuddy TE, Davis BR, Geltman EM, Goldman S, Flaker GC, et al: Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators. N Engl J Med 327:669-677, 1992
345. Ambrosioni E, Borghi C, Magnani B: The effect of the angiotensin-converting-enzyme inhibitor zofenopril on mortality and morbidity after anterior myocardial infarction. The Survival of Myocardial Infarction Long-Term Evaluation (SMILE) Study Investigators. N Engl J Med 332:80-85, 1995
346. Swedberg K, Held P, Kjekshus J, Rasmussen K, Ryden L, Wedel H: Effects of the early administration of enalapril on mortality in patients with acute myocardial infarction. Results of the Cooperative New Scandinavian Enalapril Survival Study II (CONSENSUS II). N Engl J Med 327:678-684, 1992
347. ISIS-4: A randomised factorial trial assessing early oral captopril, oral mononitrate, and intravenous magnesium sulphate in 58,050 patients with suspected acute myocardial infarction. ISIS-4 (Fourth International Study of Infarct Survival) Collaborative Group. Lancet 345:669-685, 1995
348. Pfeffer MA, Lamas GA, Vaughan DE, Parisi AF, Braunwald E: Effect of captopril on progressive ventricular dilatation after anterior myocardial infarction. N Engl J Med 319:80-86, 1988
349. Schmieder RE, Martus P, Klingbeil A: Reversal of left ventricular hypertrophy in essential hypertension. A meta-analysis of randomized double-blind studies. JAMA 275:1507-1513, 1996
350. Hansson L, Lindholm LH, Niskanen L, Lanke J, Hedner T, Niklason A, Luomanmaki K, Dahlof B, de Faire U, Morlin C, Karlberg BE, Wester PO, Bjorck JE: Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: The Captopril Prevention Project (CAPPP) randomised trial. Lancet 353:611-616, 1999
351. Niskanen L, Hedner T, Hansson L, Lanke J, Niklason A: Reduced cardiovascular morbidity and mortality in hypertensive diabetic patients on first-line therapy with an ACE inhibitor compared with a diuretic/beta-blocker-based treatment regimen: A subanalysis of the Captopril Prevention Project. Diabetes Care 24:2091-2096, 2001
352. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: Results of the HOPE study and MICRO-HOPE substudy. Heart Outcomes Prevention Evaluation Study Investigators. Lancet 355:253-259, 2000
352a. Wing LM, Reid CM, Ryan P, Beilin LJ, Brown MA, Jennings GL, Johnston CI, McNeil JJ, Macdonald GJ, Marley JE, Morgan TO, West MJ, Second Australian National Blood Pressure Study Group: A comparison of outcomes with angiotensin-converting–enzyme inhibitors and diuretics for hypertension in the elderly. N Engl J Med 348:583-592, 2003
353. Lindholm LH, Ibsen H, Dahlof B, Devereux RB, Beevers G, de Faire U, Fyhrquist F, Julius S, Kjeldsen SE, Kristiansson K, Lederballe-Pedersen O, Nieminen MS, Omvik P, Oparil S, Wedel H, Aurup P, Edelman J, Snapinn S: Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): A randomised trial against atenolol. Lancet 359:1004-1010, 2002
354. Siscovick DS, Raghunathan TE, Psaty BM, Koepsell TD, Wicklund KG, Lin X, Cobb L, Rautaharju PM, Copass MK, Wagner EH: Diuretic therapy for hypertension and the risk of primary cardiac arrest. N Engl J Med 330:1852-1857, 1994
355. Shotan A, Widerhorn J, Hurst A, Elkayam U: Risks of angiotensin-converting enzyme inhibition during pregnancy: Experimental and clinical evidence, potential mechanisms, and recommendations for use. Am J Med 96:451-456, 1994
356. Abernethy DR, Schwartz JB: Calcium-antagonist drugs. N Engl J Med 341:1447-1457, 1999
357. Bakris GL: Effects of diltiazem or lisinopril on massive proteinuria associated with diabetes mellitus. Ann Intern Med 112:707-708, 1990
358. Bakris GL, Barnhill BW, Sadler R: Treatment of arterial hypertension in diabetic humans: Importance of therapeutic selection. Kidney Int 41:912-919, 1992
359. Bohlen L, de Courten M, Weidmann P: Comparative study of the effect of ACE-inhibitors and other antihypertensive agents on proteinuria in diabetic patients. Am J Hypertens 7:84S-92S, 1994
360. Bakris GL, Weir MR, DeQuattro V, McMahon FG: Effects of an ACE inhibitor/calcium antagonist combination on proteinuria in diabetic nephropathy. Kidney Int 54:1283-1289, 1998
361. Effect of verapamil on mortality and major events after acute myocardial infarction (the Danish Verapamil Infarction Trial II–DAVIT II). Am J Cardiol 66:779-785, 1990
362. Pepine CJ, Handberg EM, Cooper-DeHoff RM, Marks RG, Kowey P, Messerli FH, Mancia G, Cangiano JL, Garcia-Barreto D, Keltai M, Erdine S, Bristol HA, Kolb HR, Bakris GL, Cohen JD, Parmley WW: A calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease. The International Verapamil-Trandolapril Study (INVEST): A randomized controlled trial. JAMA 290:2805-2816, 2003
362a. Black HR, Elliott WJ, Grandits G, Grambsh P, Lucente T, White WB, Neaton JD, Grimm RH Jr, Hansson L, Lacourcierce Y, Muller J, Sleight P, Weber MA, Williams G, Wittes J, Zanchetti A, Anders RJ: Principal results of the Controlled Onset Verapamil Investigation of Cardiovascular End Points (CONVINCE) trial. JAMA 289:2073-2082, 2003
363. The effect of diltiazem on mortality and reinfarction after myocardial infarction. The Multicenter Diltiazem Postinfarction Trial Research Group. N Engl J Med 319:385-392, 1988
364. Hansson L, Hedner T, Lund-Johansen P, Kjeldsen SE, Lindholm LH, Syvertsen JO, Lanke J, de Faire U, Dahlof B, Karlberg BE: Randomised trial of effects of calcium antagonists compared with diuretics and beta-blockers on cardiovascular morbidity and mortality in hypertension: The Nordic Diltiazem (NORDIL) study. Lancet 356:359-365, 2000
365. Calcium antagonist caution. Lancet 337:885-886, 1991
366. Schrier RW, Estacio RO: Additional follow-up from the ABCD trial in patients with type 2 diabetes and hypertension. N Engl J Med 343:1969, 2000
367. Brown MJ, Palmer CR, Castaigne A, de Leeuw PW, Mancia G, Rosenthal T, Ruilope LM: Morbidity and mortality in patients randomised to double-blind treatment with a long-acting calcium-channel blocker or diuretic in the International Nifedipine GITS study: Intervention as a Goal in Hypertension Treatment (INSIGHT). Lancet 356:366-372, 2000
368. Tatti P, Pahor M, Byington RP, Di Mauro P, Guarisco R, Strollo G, Strollo F: Outcome results of the Fosinopril Versus Amlodipine Cardiovascular Events Randomized Trial (FACET) in patients with hypertension and NIDDM. Diabetes Care 21:597-603, 1998
369. Staessen JA, Fagard R, Thijs L, Celis H, Arabidze GG, Birkenhager WH, Bulpitt CJ, de Leeuw PW, Dollery CT, Fletcher AE, Forette F, Leonetti G, Nachev C, O’Brien ET, Rosenfeld J, Rodicio JL, Tuomilehto J, Zanchetti A: Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. The Systolic Hypertension in Europe (Syst-Eur) Trial Investigators. Lancet 350:757-764, 1997
370. Wang JG, Staessen JA, Gong L, Liu L: Chinese trial on isolated systolic hypertension in the elderly. Systolic Hypertension in China (Syst-China) Collaborative Group. Arch Intern Med 160:211-220, 2000
371. Hansson L, Zanchetti A, Carruthers SG, Dahlof B, Elmfeldt D, Julius S, Menard J, Rahn KH, Wedel H, Westerling S: Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: Principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group. Lancet 351:1755-1762, 1998
372. Gradman AH, Cutler NR, Davis PJ, Robbins JA, Weiss RJ, Wood BC: Combined enalapril and felodipine extended release (ER) for systemic hypertension. Enalapril-Felodipine ER Factorial Study Group. Am J Cardiol 79:431-435, 1997
373. Oster Jr, Epstein M: Use of centrally acting sympatholytic agents in the management of hypertension. Arch Intern Med 151:1638-1644, 1991
374. Vanholder R, Carpentier J, Schurgers M, Clement DL: Rebound phenomenon during gradual withdrawal of clonidine. BMJ 1:1138, 1977
375. Metz S, Klein C, Morton N: Rebound hypertension after discontinuation of transdermal clonidine therapy. Am J Med 82:17-19, 1987
376. Khoury AF, Kaplan NM: Alpha-blocker therapy of hypertension. An unfulfilled promise. JAMA 266:394-398, 1991
377. Major cardiovascular events in hypertensive patients randomized to doxazosin vs chlorthalidone: The antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). ALLHAT Collaborative Research Group. JAMA 283:1967-1975, 2000
378. Sica DA, Gehr TW: Direct vasodilators and their role in hypertension management: Minoxidil. J Clin Hypertens 3:110-114, 2001
379. Reichgott MJ: Minoxidil and pericardial effusion: An idiosyncratic reaction. Clin Pharmacol Ther 30:64-70, 1981
380. Javier R, Dumler F, Park JH, Bok DV, Riley RW, Levin NW: Long-term treatment with minoxidil in patients with severe renal failure. J Cardiovasc Pharmacol 2:S149-S155, 1980 (suppl 2)
381. Zarate A, Gelfand MC, Horton JD, Winchester JF, Gottlieb MJ, Lazarus JM, Schreiner GE: Pericardial effusion associated with minoxidil therapy in dialyzed patients. Int J Artif Organs 3:15-17, 1980
382. Julien J, Dufloux MA, Prasquier R, Chatellier G, Menard D, Plouin PF, Menard J, Corvol P: Effects of captopril and minoxidil on left ventricular hypertrophy in resistant hypertensive patients: A 6 month double-blind comparison. J Am Coll Cardiol 16:137-142, 1990
383. Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, Palensky J, Wittes J: The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 341:709-717, 1999
384. Cicoira M, Zanolla L, Rossi A, Golia G, Franceschini L, Brighetti G, Marino P, Zardini P: Long-term, dose-dependent effects of spironolactone on left ventricular function and exercise tolerance in patients with chronic heart failure. J Am Coll Cardiol 40:304-310, 2002
385. Pitt B, Remme W, Zannad F, Neaton J, Martinez F, Roniker B, Bittman R, Hurley S, Kleiman J, Gatlin M: Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 348:1309-1321, 2003
386. Epstein M: Aldosterone as a mediator of progressive renal disease: Pathogenetic and clinical implications. Am J Kidney Dis 37:677-688, 2001
387. Bakris GL: Maximizing cardiorenal benefit in the management of hypertension: Achieve blood pressure goals. J Clin Hypertens 1:141-147, 1999
388. Will EJ: Aiming at averages. J R Soc Med 94:617-619, 2001
389. Richardson D, Bartlett C, Will EJ: Intervention thresholds and ceilings can determine the haemoglobin outcome distribution in a haemodialysis population. Nephrol Dial Transplant 15:2007-2013, 2000
390. Will EJ: Target practice. Int J Artif Organs 21:433-436, 1998
391. Grabe DW, Low CL, Bailie GR, Eisele G: Evaluation of drug-related problems in an outpatient hemodialysis unit and the impact of a clinical pharmacist. Clin Nephrol 47:117-121, 1997
392. Kaplan B, Shimp LA, Mason NA, Ascione FJ: Chronic hemodialysis patients. Part II: Reducing drug-related problems through application of the focused drug therapy review program. Ann Pharmacother 28:320-324, 1994
393. Kaplan B, Mason NA, Shimp LA, Ascione FJ: Chronic hemodialysis patients. Part I: Characterization and drug-related problems. Ann Pharmacother 28:316-319, 1994
394. Tang I, Vrahnos D, Hatoum H, Lau A: Effectiveness of clinical pharmacist interventions in a hemodialysis unit. Clin Ther 15:459-464 (discussion 432), 1993
395. US Renal Data System. USRDS 2002 Annual Report, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases. Bethesda, MD, 2002
396. Brocco E, Fioretto P, Mauer M, Saller A, Carraro A, Frigato F, Chiesura-Corona M, Bianchi L, Baggio B, Maioli M, Abaterusso C, Velussi M, Sambataro M, Virgili F, Ossi E, Nosadini R: Renal structure and function in non-insulin dependent diabetic patients with microalbuminuria. Kidney Int Suppl 63:S40-S44, 1997
397. Dalla Vestra M, Saller A, Bortoloso E, Mauer M, Fioretto P: Structural involvement in type 1 and type 2 diabetic nephropathy. Diabetes Metab 26:8-14, 2000 (suppl 4)
398. Summary of Revisions for the 2003 Clinical Practice Recommendations. Diabetes Care 26:S3, 2003
399. Go RC, Desmond R, Roseman JM, Bell DS, Vanichanan C, Acton RT: Prevalence and risk factors of microalbuminuria in a cohort of African-American women with gestational diabetes. Diabetes Care 24:1764-1769, 2001
400. Parving HH, Hommel E, Mathiesen E, Skott P, Edsberg B, Bahnsen M, Lauritzen M, Hougaard P, Lauritzen E: Prevalence of microalbuminuria, arterial hypertension, retinopathy and neuropathy in patients with insulin dependent diabetes. BMJ 296:156-160, 1988
401. Wachtell K, Palmieri V, Olsen MH, Bella JN, Aalto T, Dahlof B, Gerdts E, Wright JT Jr, Papademetriou V, Mogensen CE, Borch-Johnsen K, Ibsen H, Devereux RB: Urine albumin/creatinine ratio and echocardiographic left ventricular structure and function in hypertensive patients with electrocardiographic left ventricular hypertrophy: The LIFE study. Losartan Intervention for Endpoint Reduction. Am Heart J 143:319-326, 2002
402. Tobe SW, McFarlane PA, Naimark DM: Microalbuminuria in diabetes mellitus. CMAJ 167:499-503, 2002
403. de Courten MP, Pettitt DJ, Knowler WC: Hypertension in Pima Indians: Prevalence and predictors. Public Health Rep 111:40-43, 1996 (suppl 2)
404. Perry HM Jr, Miller JP, Fornoff Jr, Baty JD, Sambhi MP, Rutan G, Moskowitz DW, Carmody SE: Early predictors of 15-year end-stage renal disease in hypertensive patients. Hypertension 25:587-594, 1995
405. Klag MJ, Whelton PK, Randall BL, Neaton JD, Brancati FL, Ford CE, Shulman NB, Stamler J: Blood pressure and end-stage renal disease in men. N Engl J Med 334:13-18, 1996
406. Bakris GL, Weir MR, Shanifar S, Zhang Z, Douglas J, van Dijk DJ, Brenner BM: Effects of blood pressure level on progression of diabetic nephropathy: Results from the RENAAL study. Arch Intern Med 163:1555-1565, 2003
407. Estacio RO, Jeffers BW, Gifford N, Schrier RW: Effect of blood pressure control on diabetic microvascular complications in patients with hypertension and type 2 diabetes. Diabetes Care 23:B54-B64, 2000 (suppl 2)
408. Lewis EJ, Hunsicker LG, Bain RP, Rohde RD: The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. N Engl J Med 329:1456-1462, 1993 (erratum 330:152, 1993)
409. Laffel LM, McGill JB, Gans DJ: The beneficial effect of angiotensin-converting enzyme inhibition with captopril on diabetic nephropathy in normotensive IDDM patients with microalbuminuria. North American Microalbuminuria Study Group. Am J Med 99:497-504, 1995
410. Viberti G, Mogensen CE, Groop LC, Pauls JF: Effect of captopril on progression to clinical proteinuria in patients with insulin-dependent diabetes mellitus and microalbuminuria. European Microalbuminuria Captopril Study Group [see comments]. JAMA 271:275-279, 1994
411. Mathiesen ER, Hommel E, Giese J, Parving HH: Efficacy of captopril in postponing nephropathy in normotensive insulin dependent diabetic patients with microalbuminuria. BMJ 303:81-87, 1991
412. Schnack C, Hoffmann W, Hopmeier P, Schernthaner G: Renal and metabolic effects of 1-year treatment with ramipril or atenolol in NIDDM patients with microalbuminuria. Diabetologia 39:1611-1616, 1996
413. Agardh CD, Garcia-Puig J, Charbonnel B, Angelkort B, Barnett AH: Greater reduction of urinary albumin excretion in hypertensive type II diabetic patients with incipient nephropathy by lisinopril than by nifedipine. J Hum Hypertens 10:185-192, 1996
414. De Cesaris R, Ranieri G, Andriani A, Lamontanara G, Cavallo A, Bonfantino MV, Bertocchi F: Effects of benazepril and nicardipine on microalbuminuria in normotensive and hypertensive patients with diabetes. Clin Pharmacol Therapeutics 60:472-478, 1996
415. Chan JC, Cockram CS, Nicholls MG, Cheung CK, Swaminathan R: Comparison of enalapril and nifedipine in treating non-insulin dependent diabetes associated with hypertension: One year analysis. BMJ 305:981-985, 1992
416. Trevisan R, Tiengo A: Effect of low-dose ramipril on microalbuminuria in normotensive or mild hypertensive non-insulin-dependent diabetic patients. North-East Italy Microalbuminuria Study Group. Am J Hypertens 8:876-883, 1995
417. Ravid M, Lang R, Rachmani R, Lishner M: Long-term renoprotective effect of angiotensin-converting enzyme inhibition in non-insulin-dependent diabetes mellitus. A 7-year follow-up study. Arch Intern Med 156:286-289, 1996
417a. Ravid M, Savin H, Jutrin I, Tamir B, Katz B, Lishner M: Long-term stabilizing effect of angiotensin-converting enzyme inhibition on plasma creatine and on proteinuria in normotensive type II diabetic patients. Ann Intern Med 118:572-581, 1993
418. Should all patients with type 1 diabetes mellitus and microalbuminuria receive angiotensin-converting enzyme inhibitors? A meta-analysis of individual patient data. Ann Intern Med 134:370-379, 2001
419. Lewis JB, Berl T, Bain RP, Rohde RD, Lewis EJ: Effect of intensive blood pressure control on the course of type 1 diabetic nephropathy. Collaborative Study Group. Am J Kidney Dis 34:809-817, 1999
420. Parving HH, Hovind P: Microalbuminuria in type 1 and type 2 diabetes mellitus: Evidence with angiotensin converting enzyme inhibitors and angiotensin II receptor blockers for treating early and preventing clinical nephropathy. Curr Hypertens Rep 4:387-393, 2002
421. Bakris GL, Slataper R, Vicknair N, Sadler R: ACE inhibitor mediated reductions in renal size and microalbuminuria in normotensive, diabetic subjects. J Diabetes Complications 8:2-6, 1994
422. Tarnow L, Sato A, Ali S, Rossing P, Nielsen FS, Parving HH: Effects of nisoldipine and lisinopril on left ventricular mass and function in diabetic nephropathy. Diabetes Care 22:491-494, 1999
423. Schrier RW, Estacio RO, Esler A, Mehler P: Effects of aggressive blood pressure control in normotensive type 2 diabetic patients on albuminuria, retinopathy and strokes. Kidney Int 61:1086-1097, 2002
424. Velussi M, Brocco E, Frigato F, Zolli M, Muollo B, Maioli M, Carraro A, Tonolo G, Fresu P, Cernigoi AM, Fioretto P, Nosadini R: Effects of cilazapril and amlodipine on kidney function in hypertensive NIDDM patients. Diabetes 45:216-222, 1996
425. Mogensen CE, Neldam S, Tikkanen I, Oren S, Viskoper R, Watts RW, Cooper ME: Randomised controlled trial of dual blockade of renin-angiotensin system in patients with hypertension, microalbuminuria, and non-insulin dependent diabetes: The candesartan and lisinopril microalbuminuria (CALM) study [see comments]. BMJ 321:1440-1444, 2000
426. Bakris GL, Weir M: ACE inhibitors and protection against kidney disease progression in patients with type 2 diabetes: What’s the evidence. J Clin Hypertens 4:420-423, 2002
427. Bakris GL, Smith AC, Richardson DJ, Hung E, Preston R, Goldberg R, Epstein M: Impact of an ACE inhibitor and calcium antagonist on microalbuminuria and lipid subfractions in type 2 diabetes: A randomised, multi-centre pilot study. J Hum Hypertens 16:185-191, 2002
428. Weir MR, Smith DH, Neutel JM, Bedigian MP: Valsartan alone or with a diuretic or ACE inhibitor as treatment for African American hypertensives: Relation to salt intake. Am J Hypertens 14:665-671, 2001
429. Bakris GL: The role of combination antihypertensive therapy and the progression of renal disease hypertension: Looking toward the next millennium. Am J Hypertens 11:158S-162S, 1998
430. Melian EB, Jarvis B: Candesartan cilexetil plus hydrochlorothiazide combination: A review of its use in hypertension. Drugs 62:787-816, 2002
431. Maki DD, Ma JZ, Louis TA, Kasiske BL: Long-term effects of antihypertensive agents on proteinuria and renal function. Arch Intern Med 155:1073-1080, 1995
432. Gansevoort RT, Sluiter WJ, Hemmelder MH, de Zeeuw D, de Jong PE: Antiproteinuric effect of blood-pressure-lowering agents: A meta-analysis of comparative trials. Nephrol Dial Transplant 10:1963-1974, 1995
433. Chan JC, Critchley JA, Tomlinson B, Chan TY, Cockram CS: Antihypertensive and anti-albuminuric effects of losartan potassium and felodipine in Chinese elderly hypertensive patients with or without non-insulin-dependent diabetes mellitus. Am J Nephrol 17:72-80, 1997
434. Viberti G, Wheeldon NM: Microalbuminuria reduction with valsartan in patients with type 2 diabetes mellitus: A blood pressure-independent effect. Circulation 106:672-678, 2002
435. Sica DA, Bakris GL: Type 2 diabetes: RENAAL and IDNT—The emergence of new treatment options. J Clin Hypertens 4:52-57, 2002
435a. Smith AC, Toto R, Bakris GL: Differential effects of calcium channel blockers on size selectivity of proteinuria in diabetic glomerulopathy. Kidney Int 54:889-896, 1998
436. Bakris GL, Mangrum A, Copley JB, Vicknair N, Sadler R: Effect of calcium channel or beta-blockade on the progression of diabetic nephropathy in African Americans. Hypertension 29:744-750, 1997
437. Jacobsen P, Andersen S, Rossing K, Jensen BR, Parving HH: Dual blockade of the renin-angiotensin system versus maximal recommended dose of ACE inhibition in diabetic nephropathy. Kidney Int 63:1874-1880, 2003
438. Jacobsen P, Andersen S, Jensen BR, Parving HH: Additive effect of ACE inhibition and angiotensin II receptor blockade in type I diabetic patients with diabetic nephropathy. J Am Soc Nephrol 14:992-999, 2003
439. Koshy S, Bakris GL: Therapeutic approaches to achieve desired blood pressure goals: Focus on calcium channel blockers. Cardiovasc Drugs Ther 14:295-301, 2000
440. Hart PD, Bakris GL: Managing hypertension in the diabetic patient, in Egan BM, Basile JN, Lackland DT (eds): Hot Topics in Hypertension. Philadelphia, PA, Hanley and Belfus, 2004, pp 249-252
441. 2003 European Society of Hypertension-European Society of Cardiology guidelines for the management of arterial hypertension. J Hypertens 21:1011-1053, 2003
442. Levey AS: Clinical practice. Nondiabetic kidney disease. N Engl J Med 347:1505-1511, 2002
443. Walker WG, Neaton JD, Cutler JA, Neuwirth R, Cohen JD: Renal function change in hypertensive members of the Multiple Risk Factor Intervention Trial. Racial and treatment effects. The MRFIT Research Group. JAMA 268:3085-3091, 1992
444. Klag MJ, Whelton PK, Randall BL, Neaton JD, Brancati FL, Stamler J: End-stage renal disease in African-American and white men. 16-year MRFIT findings. JAMA 277:1293-1298, 1997
445. Young JH, Klag MJ, Muntner P, Whyte JL, Pahor M, Coresh J: Blood pressure and decline in kidney function: Findings from the Systolic Hypertension in the Elderly Program (SHEP). J Am Soc Nephrol 13:2776-2782, 2002
446. Klahr S, Levey AS, Beck GJ, Caggiula AW, Hunsicker L, Kusek JW, Striker G: The effects of dietary protein restriction and blood-pressure control on the progression of chronic renal disease. Modification of Diet in Renal Disease Study Group [see comments]. N Engl J Med 330:877-884, 1994
447. Maschio G, Alberti D, Janin G, Locatelli F, Mann JF, Motolese M, Ponticelli C, Ritz E, Zucchelli P: Effect of the angiotensin-converting-enzyme inhibitor benazepril on the progression of chronic renal insufficiency. The Angiotensin-Converting-Enzyme Inhibition in Progressive Renal Insufficiency Study Group [see comments]. N Engl J Med 334:939-945, 1996
448. Maschio G, Alberti D, Locatelli F, Mann JF, Motolese M, Ponticelli C, Ritz E, Janin G, Zucchelli P: Angiotensin-converting enzyme inhibitors and kidney protection: the AIPRI trial. The ACE Inhibition in Progressive Renal Insufficiency (AIPRI) Study Group. J Cardiovasc Pharmacol 33:S16-S20, 1999 (suppl 1)
449. Ruggenenti P, Perna A, Gherardi G, Garini G, Zoccali C, Salvadori M, Scolari F, Schena FP, Remuzzi G: Renoprotective properties of ACE-inhibition in non-diabetic nephropathies with non-nephrotic proteinuria [see comments]. Lancet 354:359-364, 1999
450. Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. The GISEN Group (Gruppo Italiano di Studi Epidemiologici in Nefrologia) [see comments]. Lancet 349:1857-1863, 1997
451. Dyadyk AI, Bagriy AE, Lebed IA, Yarovaya NF, Schukina EV, Taradin GG: ACE inhibitors captopril and enalapril induce regression of left ventricular hypertrophy in hypertensive patients with chronic renal failure. Nephrol Dial Transplant 12:945-951, 1997
452. Hannedouche T, Landais P, Goldfarb B, el Esper N, Fournier A, Godin M, Durand D, Chanard J, Mignon F, Suo JM: Randomised controlled trial of enalapril and beta blockers in non-diabetic chronic renal failure. BMJ 309:833-837, 1994
453. Cinotti GA, Zucchelli PC: Effect of Lisinopril on the progression of renal insufficiency in mild proteinuric non-diabetic nephropathies. Nephrol Dial Transplant 16:961-966, 2001
454. Agodoa LY, Appel L, Bakris GL, Beck G, Bourgoignie J, Briggs JP, Charleston J, Cheek D, Cleveland W, Douglas JG, Douglas M, Dowie D, Faulkner M, Gabriel A, Gassman J, Greene T, Hall Y, Hebert L, Hiremath L, Jamerson K, Johnson CJ, Kopple J, Kusek J, Lash J, Lea J, Lewis JB, Lipkowitz M, Massry S, Middleton J, Miller ER 3rd, Norris K, O’Connor D, Ojo A, Phillips RA, Pogue V, Rahman M, Randall OS, Rostand S, Schulman G, Smith W, Thornley-Brown D, Tisher CC, Toto RD, Wright JT Jr, Xu S: Effect of ramipril vs amlodipine on renal outcomes in hypertensive nephrosclerosis: A randomized controlled trial. JAMA 285:2719-2728, 2001
455. Suzuki H, Moriwaki K, Kanno Y, Nakamoto H, Okada H, Chen XM: Comparison of the effects of an ACE inhibitor and alphabeta blocker on the progression of renal failure with left ventricular hypertrophy: Preliminary report. Hypertens Res 24:153-158, 2001
456. van Essen GG, Apperloo AJ, Rensma PL, Stegeman CA, Sluiter WJ, de Zeeuw D, de Jong PE: Are angiotensin converting enzyme inhibitors superior to beta blockers in retarding progressive renal function decline? Kidney Int Suppl 63:S58-S62, 1997
457. Nakao N, Yoshimura A, Morita H, Takada M, Kayano T, Ideura T: Combination treatment of angiotensin-II receptor blocker and angiotensin-converting-enzyme inhibitor in non-diabetic renal disease (COOPERATE): A randomised controlled trial [comment]. Lancet 361:117-124, 2003 (erratum 361:1230, 2003)
458. Jafar TH, Schmid CH, Landa M, Giatras I, Toto R, Remuzzi G, Maschio G, Brenner BM, Kamper A, Zucchelli P, Becker G, Himmelmann A, Bannister K, Landais P, Shahinfar S, de Jong PE, de Zeeuw D, Lau J, Levey AS: Angiotensin-converting enzyme inhibitors and progression of nondiabetic renal disease. A meta-analysis of patient-level data. Ann Intern Med 135:73-87, 2001
459. Jafar TH, Stark PC, Schmid CH, Landa M, Maschio G, Marcantoni C, de Jong PE, de Zeeuw D, Shahinfar S, Ruggenenti P, Remuzzi G, Levey AS: Proteinuria as a modifiable risk factor for the progression of non-diabetic renal disease. Kidney Int 60:1131-1140, 2001
460. Laverman GD, Navis G, Henning RH, de Jong PE, de Zeeuw D: Dual renin-angiotensin system blockade at optimal doses for proteinuria. Kidney Int 62:1020-1025, 2002
461. Nielsen S, Dollerup J, Nielsen B, Jensen HA, Mogensen CE: Losartan reduces albuminuria in patients with essential hypertension. An enalapril controlled 3 months study. Nephrol Dial Transplant 12:19-23, 1997 (suppl 2)
462. Remuzzi A, Perico N, Sangalli F, Vendramin G, Moriggi M, Ruggenenti P, Remuzzi G: ACE inhibition and ANG II receptor blockade improve glomerular size-selectivity in IgA nephropathy. Am J Physiol 276:F457-F466, 1999
463. Bidani AK, Griffin KA, Bakris G, Picken MM: Lack of evidence of blood pressure-independent protection by renin-angiotensin system blockade after renal ablation. Kidney Int 57:1651-1661, 2000
464. Nakao N, Yoshimura A, Morita H, Takada M, Kayano T, Ideura T: Combination treatment of angiotensin-II receptor blocker and angiotensin-converting-enzyme inhibitor in non-diabetic renal disease (COOPERATE): A randomised controlled trial. Lancet 361:117-124, 2003
465. Segura J, Praga M, Campo C, Rodicio JL, Ruilope LM: Combination is better than monotherapy with ACE inhibitor or angiotensin receptor antagonist at recommended doses. J Renin Angiotensin Aldosterone Syst 4:43-47, 2003
466. Klahr S, Levey AS, Beck GJ, Caggiula AW, Hunsicker L, Kusek JW, Striker G: The effects of dietary protein restriction and blood-pressure control on the progression of chronic renal disease. Modification of Diet in Renal Disease Study Group. N Engl J Med 330:877-884, 1994
467. Peterson JC, Adler S, Burkart JM, Greene T, Hebert LA, Hunsicker LG, King AJ, Klahr S, Massry SG, Seifter JL: Blood pressure control, proteinuria, and the progression of renal disease. The Modification of Diet in Renal Disease Study. Ann Intern Med 123:754-762, 1995
468. Toto RD, Mitchell HC, Smith RD, Lee HC, McIntire D, Pettinger WA: "Strict" blood pressure control and progression of renal disease in hypertensive nephrosclerosis. Kidney Int 48:851-859, 1995
469. Pahor M, Shorr RI, Somes GW, Cushman WC, Ferrucci L, Bailey JE, Elam JT, Applegate WB: Diuretic-based treatment and cardiovascular events in patients with mild renal dysfunction enrolled in the systolic hypertension in the elderly program. Arch Intern Med 158:1340-1345, 1998
470. Walker WG, Neaton JD, Cutler JA, Neuwirth R, Cohen JD: Renal function change in hypertensive members of the Multiple Risk Factor Intervention Trial. Racial and treatment effects. The MRFIT Research Group [see comments]. JAMA 268:3085-3091, 1992
471. Jafar TH, Stark PC, Schmid CH, Landa M, Maschio G, de Jong PE, de Zeeuw D, Shahinfar S, Toto R, Levey AS: Progression of chronic kidney disease: Blood pressure control, proteinuria, and angiotensin-converting enzyme inhibition. Ann Intern Med 139:244-252, 2003
472. Vincenti F, Jensik SC, Filo RS, Miller J, Pirsch J: A long-term comparison of tacrolimus (FK506) and cyclosporine in kidney transplantation: Evidence for improved allograft survival at five years. Transplantation 73:775-782, 2002
473. Opelz G, Wujciak T, Ritz E: Association of chronic kidney graft failure with recipient blood pressure. Collaborative Transplant Study. Kidney Int 53:217-222, 1998
474. Brazy PC, Pirsch JD, Belzer FO: Factors affecting renal allograft function in long-term recipients. Am J Kidney Dis 19:558-566, 1992
475. Fernandez-Fresnedo G, Palomar R, Escallada R, Martin de Francisco AL, Cotorruelo JG, Zubimendi JA, Sanz de Castro S, Ruiz JC, Rodrigo E, Arias M: Hypertension and long-term renal allograft survival: Effect of early glomerular filtration rate. Nephrol Dial Transplant 16:105-109, 2001 (suppl 1)
476. Mange KC, Cizman B, Joffe M, Feldman HI: Arterial hypertension and renal allograft survival. JAMA 283:633-638, 2000
477. Zayas CF, Guasch A: Early glomerular dysfunction in human renal allografts. Kidney Int 60:1938-1947, 2001
478. Olyaei AJ, de Mattos AM, Bennett WM: Nephrotoxicity of immunosuppressive drugs: New insight and preventive strategies. Curr Opin Crit Care 7:384-389, 2001
479. van den Dorpel MA, Zietse R, Ijzermans JN, Weimar W: Prophylactic isradipine treatment after kidney transplantation: A prospective double-blind placebo-controlled randomized trial. Transplant Int 7:S270-274, 1994 (suppl 1)
480. Midtvedt K, Ihlen H, Hartmann A, Bryde P, Bjerkely BL, Foss A, Fauchald P, Holdaas H: Reduction of left ventricular mass by lisinopril and nifedipine in hypertensive renal transplant recipients: A prospective randomized double-blind study. Transplantation 72:107-111, 2001
481. VenkatRaman G, Feehally J, Coates RA, Elliott HL, Griffin PJ, Olubodun JO, Wilkinson R: Renal effects of amlodipine in normotensive renal transplant recipients. Nephrol Dial Transplant 14:384-388, 1999
482. Midtvedt K, Hartmann A, Foss A, Fauchald P, Nordal KP, Rootwelt K, Holdaas H: Sustained improvement of renal graft function for two years in hypertensive renal transplant recipients treated with nifedipine as compared to lisinopril [see comments.]. Transplantation 72:1787-1792, 2001
483. Mourad G, Ribstein J, Mimran A: Converting-enzyme inhibitor versus calcium antagonist in cyclosporine-treated renal transplants. Kidney Int . 43:419-425, 1993
484. Hausberg M, Barenbrock M, Hohage H, Muller S, Heidenreich S, Rahn KH: ACE inhibitor versus beta-blocker for the treatment of hypertension in renal allograft recipients. Hypertension. 33:862-868, 1999
485. van Riemsdijk IC, Mulder PG, de Fijter JW, Bruijn JA, van Hooff JP, Hoitsma AJ, Tegzess AM, Weimar W: Addition of isradipine (Lomir) results in a better renal function after kidney transplantation: A double-blind, randomized, placebo-controlled, multi-center study. Transplantation. 70:122-126, 2000
486. Rahn KH, Barenbrock M, Fritschka E, Heinecke A, Lippert J, Schroeder K, Hauser I, Wagner K, Neumayer HH: Effect of nitrendipine on renal function in renal-transplant patients treated with cyclosporin: A randomised trial. Lancet 354:1415-1420, 1999
487. Madsen JK, Sorensen SS, Hansen HE, Pedersen EB: The effect of felodipine on renal function and blood pressure in cyclosporin-treated renal transplant recipients during the first three months after transplantation. Nephrol Dial Transplant 13:2327-2334, 1998
488. Hernandez D, Lacalzada J, Salido E, Linares J, Barragan A, Lorenzo V, Higueras L, Martin B, Rodriguez A, Laynez I, Gonzalez-Posada JM, Torres A: Regression of left ventricular hypertrophy by lisinopril after renal transplantation: Role of ACE gene polymorphism. Kidney Int 58:889-897, 2000
489. Vlahakos DV, Canzanello VJ, Madaio MP, Madias NE: Enalapril-associated anemia in renal transplant recipients treated for hypertension. Am J Kidney Dis 17:199-205, 1991
490. Gossmann J, Thurmann P, Bachmann T, Weller S, Kachel HG, Schoeppe W, Scheuermann EH: Mechanism of angiotensin converting enzyme inhibitor-related anemia in renal transplant recipients. Kidney Int 50:973-978, 1996
491. Stigant CE, Cohen J, Vivera M, Zaltzman JS: ACE inhibitors and angiotensin II antagonists in renal transplantation: An analysis of safety and efficacy. Am J Kidney Dis 35:58-63, 2000
492. Curtis JJ, Luke RG, Jones P, Diethelm AG: Hypertension in cyclosporine-treated renal transplant recipients is sodium dependent. Am J Med 85:134-138, 1988
493. Aakhus S, Dahl K, Wideroe TE: Cardiovascular morbidity and risk factors in renal transplant patients. Nephrol Dial Transplant 14:648-654, 1999
494. Kasiske BL, Chakkera HA, Roel J: Explained and unexplained ischemic heart disease risk after renal transplantation. J Am Soc Nephrol 11:1735-1743, 2000
495. Woo YM, McLean D, Kavanagh D, Ward L, Aitken S, Miller GJ, Egan P, Hughes K, Clark L, Carswell K, Morris ST, Northridge DB, Rodger RS, Jardine AG: The influence of pre-operative electrocardiographic abnormalities and cardiovascular risk factors on patient and graft survival following renal transplantation. J Nephrol 15:380-386, 2002
496. Suwelack B, Gerhardt U, Hausberg M, Rahn KH, Hohage H: Comparison of quinapril versus atenolol: Effects on blood pressure and cardiac mass after renal transplantation. Am J Cardiol 86:583-585, A510, 2000
497. Kasiske BL: Risk factors for accelerated atherosclerosis in renal transplant recipients. Am J Med 84:985-992, 1988
498. Roodnat JI, Mulder PG, Rischen-Vos J, van Riemsdijk IC, van Gelder T, Zietse R, JN IJ, Weimar W: Proteinuria after renal transplantation affects not only graft survival but also patient survival. Transplantation 72:438-444, 2001
499. Fernandez-Fresnedo G, Escallada R, Rodrigo E, De Francisco AL, Cotorruelo JG, Sanz De Castro S, Zubimendi JA, Ruiz JC, Arias M: The risk of cardiovascular disease associated with proteinuria in renal transplant patients. Transplantation 73:1345-1348, 2002
500. Hausberg M, Kosch M, Hohage H, Suwelack B, Barenbrock M, Kisters K, Rahn KH: Antihypertensive treatment in renal transplant patients—Is there a role for ACE inhibitors? Ann Transplant 6:31-37, 2001
501. Rigatto C, Foley RN, Kent GM, Guttmann R, Parfrey PS: Long-term changes in left ventricular hypertrophy after renal transplantation. Transplantation 70:570-575, 2000
502. Ferreira SR, Moises VA, Tavares A, Pacheco-Silva A: Cardiovascular effects of successful renal transplantation: A 1-year sequential study of left ventricular morphology and function, and 24-hour blood pressure profile. Transplantation 74:1580-1587, 2002
503. Marcondes AM, De Lima JJ, Giorgi DM, Vieira ML, de Andrade JL, Ianhez LE, Krieger EM: Twenty-four hour blood pressure profile and left ventricular hypertrophy early after renal transplantation. Ren Fail 24:207-213, 2002
504. Kooman JP, Christiaans MH, Boots JM, van Der Sande FM, Leunissen KM, van Hooff JP: A comparison between office and ambulatory blood pressure measurements in renal transplant patients with chronic transplant nephropathy. Am J Kidney Dis 37:1170-1176, 2001
505. Carlsen JE, Hansen FM, Jensen HA: Efficacy and safety of cilazapril in hypertensive patients with moderate to severe renal impairment. Am J Med 87:79S-82S, 1989
506. del Castillo D, Campistol JM, Guirado L, Capdevilla L, Martinez JG, Pereira P, Bravo J, Perez R: Efficacy and safety of losartan in the treatment of hypertension in renal transplant recipients. Kidney Int Suppl 68:S135-S139, 1998
507. Donohoe JF, Laher M, Doyle GD, Long C, Glover DR, Cooper WD: Lisinopril treatment of hypertension in patients with impaired renal function. Gerontology 33:S36–S41, 1987 (suppl 1)
508. Donohoe JF, Kelly J, Laher MS, Doyle GD: Lisinopril in the treatment of hypertensive patients with renal impairment. Am J Med 85:31-34, 1988
509. Fernandez-Andrade C, Russo D, Iversen B, Zucchelli P, Aranda P, Guerra L, Casado S: Comparison of losartan and amlodipine in renally impaired hypertensive patients. Kidney Int Suppl 68:S120-S124, 1998
510. Gansevoort RT, de Zeeuw D, Shahinfar S, Redfield A, de Jong PE: Effects of the angiotensin II antagonist losartan in hypertensive patients with renal disease. J Hypertens Suppl 12:S37-S42, 1994
511. Gassia JP, Durand D, Ton TH, Degroc F, Suc JM: Long term effect of captopril in hypertension with chronic renal failure. Proc Eur Dial Transplant Assoc 17:719-724, 1980
512. Haffner CA, Kendall MJ, Struthers AD, Bridges A, Stott DJ: Effects of captopril and enalapril on renal function in elderly patients with chronic heart failure. Postgrad Med J 71:287-292, 1995
513. Herlitz H, Ahlmen J, Aurell M, Blohme I, Brynger H, Delin K, Larsson O: Captopril in hypertension after renal transplantation. Scand J Urol Nephrol Suppl 79:111-114, 1984
514. Kloke HJ, Wetzels JF, van Hamersvelt HW, Koene RA, Kleinbloesem CH, Huysmans FT: Effects of nitrendipine and cilazapril on renal hemodynamics and albuminuria in hypertensive patients with chronic renal failure. J Cardiovasc Pharmacol 16:924-930, 1990
515. Kostis JB, Shelton B, Gosselin G, Goulet C, Hood WB Jr, Kohn RM, Kubo SH, Schron E, Weiss MB, Willis PW III, Young JB, Probstfield J: Adverse effects of enalapril in the Studies of Left Ventricular Dysfunction (SOLVD). SOLVD Investigators. Am Heart J 131:350-355, 1996
516. Knight EL, Glynn RJ, McIntyre KM, Mogun H, Avorn J: Predictors of decreased renal function in patients with heart failure during angiotensin-converting enzyme inhibitor therapy: Results from the studies of left ventricular dysfunction (SOLVD) [see comments]. Am Heart J 138:t-55, 1999
517. Kumagai H, Hayashi K, Kumamaru H, Saruta T: Amlodipine is comparable to angiotensin-converting enzyme inhibitor for long-term renoprotection in hypertensive patients with renal dysfunction: A one-year, prospective, randomized study. Am J Hypertens 13:980-985, 2000
518. Martinez-Castelao A, Hueso M, Sanz V, Rejas J, Alsina J, Grinyo JM: Treatment of hypertension after renal transplantation: Long-term efficacy of verapamil, enalapril, and doxazosin. Kidney Int Suppl 68:S130-S134, 1998
519. Mitchell HC, Smith RD, Cutler RE, Sica D, Videen J, Thompsen-Bell S, Jones K, Bradley-Guidry C, Toto RD: Racial differences in the renal response to blood pressure lowering during chronic angiotensin-converting enzyme inhibition: A prospective double-blind randomized comparison of fosinopril and lisinopril in older hypertensive patients with chronic renal insufficiency. Am J Kidney Dis 29:897-906, 1997
520. Mioli V, Boggi R, Greco A, Capponi E, Trivelli G, Cecchini F, Acciarri PM, Concetti M, Panichi N, Radicioni R: Enalapril in the treatment of hypertension associated with renal failure: Results from a multicenter study. Rivista Eur Sci Med Farmacol 12:127-134, 1990
521. Rachmani R, Levi Z, Slavachevsky I, Half-Onn E, Ravid M: Effect of an alpha-adrenergic blocker, and ACE inhibitor and hydrochlorothiazide on blood pressure and on renal function in type 2 diabetic patients with hypertension and albuminuria. A randomized cross-over study. Nephron 80:175-182, 1998
522. Raine AE, Ledingham JG: Clinical experience with captopril in the treatment of severe drug-resistant hypertension. Am J Cardiol 49:1475-1479, 1982
523. Rosenberg ME, Hostetter TH: Comparative effects of antihypertensives on proteinuria: Angiotensin-converting enzyme inhibitor versus alpha 1-antagonist. Am J Kidney Dis 18:472-482, 1991
524. Rucinska EJ, Small R, Irvin J: High-risk patients treated with enalapril maleate: Safety considerations. Int J Cardiol 22:249-259, 1989
525. Stumpe KO, Overlack A: A new trial of the efficacy, tolerability, and safety of angiotensin-converting enzyme inhibition in mild systemic hypertension with concomitant diseases and therapies. Perindopril Therapeutic Safety Study Group (PUTS). Am J Cardiol 71:32E-37E, 1993
525a. Perrone RD, Madias NE, Levey AS: Serum creatinine as an index of renal function: New insights into old concepts. Clin Chem 38:1933-1953, 1992
526. von Vigier RO, Zberg PM, Teuffel O, Bianchetti MG: Preliminary experience with the angiotensin II receptor antagonist irbesartan in chronic kidney disease. Eur J Pediatr 159:590-593, 2000
527. Weber M: Clinical safety and tolerability of losartan. Clin Therapeutics 19:604-616, 1997
528. Zanella MT, Mattei E Jr, Draibe SA, Kater CE, Ajzen H: Inadequate aldosterone response to hyperkalemia during angiotensin converting enzyme inhibition in chronic renal failure. Clin Pharmacol Therapeutics 38:613-617, 1985
529. Zucchelli P, Zuccala A, Borghi M, Fusaroli M, Sasdelli M, Stallone C, Sanna G, Gaggi R: Long-term comparison between captopril and nifedipine in the progression of renal insufficiency. Kidney Int 42:452-458, 1992
530. Koomans HA, Roos JC, Boer P, Geyskes GG, Mees EJ: Salt sensitivity of blood pressure in chronic renal failure. Evidence for renal control of body fluid distribution in man. Hypertension 4:190-197, 1982
531. Brater DC: Anti-inflammatory agents and renal function. Semin Arthritis Rheum 32:33-42, 2002
532. Shankar SS, Brater DC: Loop diuretics: From the Na-K-2Cl transporter to clinical use. Am J Physiol Renal Physiol 284:F11-F21, 2003
533. Brater DC: Diuretic therapy. N Engl J Med 339:387-395, 1998
534. Wilcox CS: New insights into diuretic use in patients with chronic renal disease. J Am Soc Nephrol 13:798-805, 2002
535. Sica DA, Gehr TW: Diuretic combinations in refractory oedema states: Pharmacokinetic-pharmacodynamic relationships. Clin Pharmacokinet 30:229-249, 1996
536. Wilcox CS, Mitch WE, Kelly RA, Skorecki K, Meyer TW, Friedman PA, Souney PF: Response of the kidney to furosemide. I. Effects of salt intake and renal compensation. J Lab Clin Med 102:450-458, 1983
537. Knauf H, Mutschler E: Diuretic effectiveness of hydrochlorothiazide and furosemide alone and in combination in chronic renal failure. J Cardiovasc Pharmacol 26:394-400, 1995
538. Murray MD, Haag KM, Black PK, Hall SD, Brater DC: Variable furosemide absorption and poor predictability of response in elderly patients. Pharmacotherapy 17:98-106, 1997
539. Beermann B: Aspects on pharmacokinetics of some diuretics. Acta Pharmacol Toxicol (Copenh) 54:17-29, 1984 (suppl 1)
540. Goldman P: Effect of bioavailability on dose-response relationships. Am J Med 77:47-51, 1984
541. Ellison DH: The physiologic basis of diuretic synergism: Its role in treating diuretic resistance. Ann Intern Med 114:886-894, 1991
542. Mitch WE, Wilcox CS: Disorders of body fluids, sodium and potassium in chronic renal failure. Am J Med 72:536-550, 1982
543. Wilcox C: Diuretics, in Brenner B, Rector F (eds): The Kidney (ed 6). Philadelphia, PA, W.B. Saunders, 2000, pp 2219-2252
544. Voelker Jr, Cartwright-Brown D, Anderson S, Leinfelder J, Sica DA, Kokko JP, Brater DC: Comparison of loop diuretics in patients with chronic renal insufficiency. Kidney Int 32:572-578, 1987
545. Ouzan J, Perault C, Lincoff AM, Carre E, Mertes M: The role of spironolactone in the treatment of patients with refractory hypertension. Am J Hypertens 15:333-339, 2002
546. Hutchinson T, Roy D, Seely JF: Extracellular volume contraction and hyponatremia, in Dirks JH, Sutton RA (eds): Diuretic: Physiology, Pharmacology, and Clinical Use. Philadelphia, PA, W.B. Saunders, 1986, pp 287-295
547. Sica DA: Dosage considerations with perindopril for systemic hypertension. Am J Cardiol 88:13i-18i, 2001
548. Hollifield JW: Thiazide treatment of hypertension. Effects of thiazide diuretics on serum potassium, magnesium, and ventricular ectopy. Am J Med 80:8-12, 1986
549. Ambrosioni E, Borghi C, Costa FV: Captopril and hydrochlorothiazide: Rationale for their combination. Br J Clin Pharmacol 23:43S-50S, 1987 (suppl 1)
550. Schepkens H, Vanholder R, Billiouw JM, Lameire N: Life-threatening hyperkalemia during combined therapy with angiotensin-converting enzyme inhibitors and spironolactone: An analysis of 25 cases. Am J Med 110:438-441, 2001
551. Charytan D, Goldfarb DS: Indications for hospitalization of patients with hyperkalemia. Arch Intern Med 160:1605-1611, 2000
552. Reinhart RA: Magnesium metabolism. A review with special reference to the relationship between intracellular content and serum levels. Arch Intern Med 148:2415-2420, 1988
553. Sica DA, Frishman WH, Cavusoglu E: Magnesium, potassium, and calcium as potential cardiovascular disease therapies, in Frishman W, Sonnenblick S, Sica DA (eds): Cardiovascular Pharmacotherapeutics (ed 2). New York, NY, McGraw-Hill, 2003, pp 177-190
554. Rejnmark L, Vestergaard P, Pedersen AR, Heickendorff L, Andreasen F, Mosekilde L: Dose-effect relations of loop- and thiazide-diuretics on calcium homeostasis: A randomized, double-blinded Latin-square multiple cross-over study in postmenopausal osteopenic women. Eur J Clin Invest 33:41-50, 2003
555. Bittar AE, Ratcliffe PJ, Richardson AJ, Brown RC, Woodhead JS, Morris PJ: Hyperparathyroidism, hypertension and loop diuretic medication in renal transplant recipients. Nephrol Dial Transplant 4:740-744, 1989
556. Gurwitz JH, Kalish SC, Bohn RL, Glynn RJ, Monane M, Mogun H, Avorn J: Thiazide diuretics and the initiation of anti-gout therapy. J Clin Epidemiol 50:953-959, 1997
557. Strom BL, Schinnar R, Apter AJ, Margolis DJ, Lautenbach E, Hennessy S, Bilker WB, Pettitt D: Absence of cross-reactivity between sulfonamide antibiotics and sulfonamide nonantibiotics. N Engl J Med 349:1628-1635, 2003
558. Rosenthal T, Oparil S: The effect of antihypertensive drugs on the fetus. J Hum Hypertens 16:293-298, 2002
559. Newman WP 3rd, Freedman DS, Voors AW, Gard PD, Srinivasan SR, Cresanta JL, Williamson GD, Webber LS, Berenson GS: Relation of serum lipoprotein levels and systolic blood pressure to early atherosclerosis. The Bogalusa Heart Study. N Engl J Med 314:138-144, 1986
560. Daniels SR: Hypertension-induced cardiac damage in children and adolescents. Blood Press Monit 4:165-170, 1999
561. Laird WP, Fixler DE: Left ventricular hypertrophy in adolescents with elevated blood pressure: Assessment by chest roentgenography, electrocardiography, and echocardiography. Pediatrics 67:255-259, 1981
562. Mitsnefes MM, Schwartz SM, Daniels SR, Kimball TR, Khoury P, Strife CF: Changes in left ventricular mass index in children and adolescents after renal transplantation. Pediatr Transplant 5:279-284, 2001
563. Sorof JM, Cardwell G, Franco K, Portman RJ: Ambulatory blood pressure and left ventricular mass index in hypertensive children. Hypertension 39:903-908, 2002
564. Johnstone LM, Jones CL, Grigg LE, Wilkinson JL, Walker RG, Powell HR: Left ventricular abnormalities in children, adolescents and young adults with renal disease. Kidney Int 50:998-1006, 1996
565. Scharer K, Schmidt KG, Soergel M: Cardiac function and structure in patients with chronic renal failure. Pediatr Nephrol 13:951-965, 1999
566. USRDS, Pediatric ESRD. Atlas of End Stage Renal Disease: 2001 Annual Report. Am J Kidney Dis 38:S107-S116, 2001
567. Report of the Second Task Force on Blood Pressure Control in Children—1987. Task Force on Blood Pressure Control in Children. National Heart, Lung, and Blood Institute, Bethesda, Maryland. Pediatrics 79:1-25, 1987
568. Update on the 1987 Task Force Report on High Blood Pressure in Children and Adolescents: A working group report from the National High Blood Pressure Education Program. National High Blood Pressure Education Program Working Group on Hypertension Control in Children and Adolescents. Pediatrics 98:649-658, 1996
569. Vogt BA: Hypertension in children and adolescents: Definition, pathophysiology, risk factors, and long-term sequelae. Curr Therapeutic Res 62:283-297, 2001
570. Lingens N, Freund M, Seeman T, Witte K, Lemmer B, Scharer K: Circadian blood pressure changes in untreated children with kidney disease and conserved renal function. Acta Paediatr 86:719-723, 1997
571. Reusz GS, Hobor M, Tulassay T, Sallay P, Miltenyi M: 24 hour blood pressure monitoring in healthy and hypertensive children. Arch Dis Child 70:90-94, 1994
572. Lingens N, Dobos E, Lemmer B, Scharer K: Nocturnal blood pressure elevation in transplanted pediatric patients. Kidney Int Suppl 55:S175-S176, 1996
573. Khan IA, Gajaria M, Stephens D, Balfe JW: Ambulatory blood pressure monitoring in children: A large center’s experience. Pediatr Nephrol 14:802-805, 2000
574. Sorof JM, Poffenbarger T, Portman R: Abnormal 24-hour blood pressure patterns in children after renal transplantation. Am J Kidney Dis 35:681-686, 2000
575. Flynn JT: Differentiation between primary and secondary hypertension in children using ambulatory blood pressure monitoring. Pediatrics 110:89-93, 2002
576. Calzolari A, Giordano U, Matteucci MC, Pastore E, Turchetta A, Rizzoni G, Alpert B: Hypertension in young patients after renal transplantation: Ambulatory blood pressure monitoring versus casual blood pressure. Am J Hypertens 11:497-501, 1998
577. Belsha CW, Wells TG, McNiece KL, Seib PM, Plummer JK, Berry PL: Influence of diurnal blood pressure variations on target organ abnormalities in adolescents with mild essential hypertension. Am J Hypertens 11:410-417, 1998
578. Matteucci MC, Giordano U, Calzolari A, Turchetta A, Santilli A, Rizzoni G: Left ventricular hypertrophy, treadmill tests, and 24-hour blood pressure in pediatric transplant patients. Kidney Int 56:1566-1570, 1999
579. Harmon WE: Treatment of children with chronic renal failure. Kidney Int 47:951-961, 1995
580. Fivush BA, Jabs K, Neu AM, Sullivan EK, Feld L, Kohaut E, Fine R: Chronic renal insufficiency in children and adolescents: The 1996 annual report of NAPRTCS. North American Pediatric Renal Transplant Cooperative Study. Pediatr Nephrol 12:328-337, 1998
581. Rocchini AP, Katch V, Anderson J, Hinderliter J, Becque D, Martin M, Marks C: Blood pressure in obese adolescents: Effect of weight loss. Pediatrics 82:16-23, 1988
582. Sadowski RH, Falkner B: Hypertension in pediatric patients. Am J Kidney Dis 27:305-315, 1996
583. Hagberg JM, Goldring D, Ehsani AA, Heath GW, Hernandez A, Schechtman K, Holloszy JO: Effect of exercise training on the blood pressure and hemodynamic features of hypertensive adolescents. Am J Cardiol 52:763-768, 1983
584. Hansen HS, Froberg K, Hyldebrandt N, Nielsen JR: A controlled study of eight months of physical training and reduction of blood pressure in children: The Odense schoolchild study. BMJ 303:682-685, 1991
585. Mirkin BL, Newman TJ: Efficacy and safety of captopril in the treatment of severe childhood hypertension: Report of the International Collaborative Study Group. Pediatrics 75:1091-1100, 1985
586. Soffer BA, Shahinfar S, Shaw WC, et al: Effects of ACE inhibitor, enalapril, in children age 6-16 years with hypertension. Pediatr Res 47:473A, 2000
587. Blowey DL: Antihypertensive agents: Mechanisms of action, safety profiles, and current uses in children. Curr Therapeutic Res 62:298-312, 2001
588. Franscini LM, Von Vigier RO, Pfister R, Casaulta-Aebischer C, Fossali E, Bianchetti MG: Effectiveness and safety of the angiotensin II antagonist irbesartan in children with chronic kidney diseases. Am J Hypertens 15:1057-1063, 2002
589. Cook J, Daneman D, Spino M, Sochett E, Perlman K, Balfe JW: Angiotensin converting enzyme inhibitor therapy to decrease microalbuminuria in normotensive children with insulin-dependent diabetes mellitus. J Pediatr 117:39-45, 1990
590. Trachtman H, Gauthier B: Effect of angiotensin-converting enzyme inhibitor therapy on proteinuria in children with renal disease. J Pediatr 112:295-298, 1988
591. Yuksel H, Darcan S, Kabasakal C, Cura A, Mir S, Mavi E: Effect of enalapril on proteinuria, phosphaturia, and calciuria in insulin-dependent diabetes. Pediatr Nephrol 12:648-650, 1998
592. Loirat C, Azancot A, Pillion G, Macher MA, Mouchet B, Gainet B, Mathieu H: Sequential echocardiographic study prior and during antihypertensive therapy in children with severe hypertension. Clin Exp Hypertens A 8:805-810, 1986
593. Sinaiko AR: Hypertension in children. N Engl J Med 335:1968-1973, 1996
594. Sinaiko AR, Kashtan CE, Mirkin BL: Antihypertensive drug therapy with captopril in children and adolescents. Clin Exp Hypertens A 8:829-839, 1986
595. Tack ED, Perlman JM: Renal failure in sick hypertensive premature infants receiving captopril therapy. J Pediatr 112:805-810, 1988
596. Pryde PG, Sedman AB, Nugent CE, Barr M Jr: Angiotensin-converting enzyme inhibitor fetopathy. J Am Soc Nephrol 3:1575-1582, 1993
597. Sedman AB, Kershaw DB, Bunchman TE: Recognition and management of angiotensin converting enzyme inhibitor fetopathy. Pediatr Nephrol 9:382-385, 1995
597a. Renal Association: Treatment of Adults and Children With Renal Failure: Standard and Audit Measures (ed 3). London, UK, Royal College of Physicians of London and the Renal Association, 2002
598. Molitch ME, DeFronzo RA, Franz MJ, Keane WF, Mogensen CE, Parving HH: Diabetic nephropathy. Diabetes Care 26:S94-S98, 2003 (suppl 1)
598a. Doll G, Mycinski C, Cosnay P, Alison D, Raynaud P, Brochier M: Comparison of circadian blood pressure variations in hypertensive patients with renal artery stenosis and essential hypertension. J Hum Hypertens 4:390-392, 1990
599. White WB: Ambulatory and home blood pressure monitoring, in Izzo JL, Black HR (eds): Hypertension Primer (ed 3). Dallas, TX, American Heart Association, 2003, pp 330-336
600. Staessen JA, Thijs L, Fagard R, O’Brien ET, Clement D, de Leeuw PW, Mancia G, Nachev C, Palatini P, Parati G, Tuomilehto J, Webster J: Predicting cardiovascular risk using conventional vs ambulatory blood pressure in older patients with systolic hypertension. Systolic Hypertension in Europe Trial Investigators. JAMA 282:539-546, 1999
600a. Redon J: Ambulatory blood pressure and the kidney. Blood Press Monit 3:157-161, 1998
600b. Otsuka K, Cornelissen G, Halberg F, et al: Excessive circadian amplitude of blood pressure increases risk of ischaemic stroke and nephropathy. J Med Eng Technol 21:23-30, 1997
600c. Verdecchia P, Schillaci G, Borgioni C, Ciucci A, Porcellati C: Prognostic significance of the white coat effect. Hypertension 29:1218-1224, 1997
600d. Imai Y, Abe K, Nishiyama A, Sekino M, Yoshinaga K: Evaluation of the antihypertensive effect of barnidipine, a dihydropyridine calcium entry blocker, as determined by the ambulatory blood pressure level averaged for 24 h, daytime, and nighttime. Barnidipine Study Group. Am J Hypertens 10:1415-1419, 1997
600e. Lemne C, Lindvall K, Georgiades A, Fredrikson M, de Faire U: Structural cardiac changes in relation to 24-h ambulatory blood pressure levels in borderline hypertension. J Intern Med 238:49-57, 1995
600f. Boley E, Pickering TG, James GD, de Simone G, Roman MJ, Devereux RB: Relations of ambulatory blood pressure level and variability to left ventricular and arterial function and to left ventricular mass in normotensive and hypertensive adults. Blood Press Monit 2:323-331, 1997
600g. Lantelme P, Milon H, Vernet M, Gayet C: Difference between office and ambulatory blood pressure or real white coat effect: Does it matter in terms of prognosis? J Hypertens 18:383-389, 2000
600h. Lin JM, Hsu KL, Chiang FT, Tseng CD, Tseng YZ: Influence of isolated diastolic hypertension identified by ambulatory blood pressure on target organ damage. Int J Cardiol 48:311-316, 1995
600i. Musialik D, Kosicka T, Skoluda A, Boruczkowska A, Trojnarska O, Tykarski A: Twenty-four hour ambulatory blood pressure monitoring in young and elderly hypertensive subjects. J Hum Hypertens 12:641-642, 1998
600j. Palatini P, Penzo M, Canali C, Dorigatti F, Pessina AC: Interactive action of the white-coat effect and the blood pressure levels on cardiovascular complications in hypertension. Am J Med 103:208-216, 1997
601. Hermida RC, Ayala DE: Prognostic value of office and ambulatory blood pressure measurements in pregnancy. Hypertension 40:298-303, 2002
602. Myers MG: Ambulatory blood pressure monitoring in the assessment of antihypertensive therapy. Blood Press Monit 4:185-188, 1999
603. Cottone S, Panepinto N, Vadala A, Zagarrigo C, Galione P, Volpe V, Cerasola G: Sympathetic overactivity and 24-hour blood pressure pattern in hypertensives with chronic renal failure. Ren Fail 17:751-758, 1995
604. Farmer CK, Goldsmith DJ, Cox J, Dallyn P, Kingswood JC, Sharpstone P: An investigation of the effect of advancing uraemia, renal replacement therapy and renal transplantation on blood pressure diurnal variability. Nephrol Dial Transplant 12:2301-2307, 1997
605. Keller CK, Bergis KH, Fliser D, Ritz E: Renal findings in patients with short-term type 2 diabetes. J Am Soc Nephrol 7:2627-2635, 1996
606. Kempe HP, Hasslacher C: Circadian variation of blood pressure in normo- and hypertensive diabetic patients with and without nephropathy. Z Kardiol 85:118-120, 1996 (suppl 3)
607. Poulsen PL, Ebbehoj E, Hansen KW, Mogensen CE: 24-h blood pressure and autonomic function is related to albumin excretion within the normoalbuminuric range in IDDM patients. Diabetologia 40:718-725, 1997
608. Nielsen FS, Gaede P, Vedel P, Pedersen O, Parving HH: White coat hypertension in NIDDM patients with and without incipient and overt diabetic nephropathy. Diabetes Care 20:859-863, 1997
609. Bauduceau B, Genes N, Chamontin B, Vaur L, Renault M, Etienne S, Marre M: Ambulatory blood pressure and urinary albumin excretion in diabetic (non-insulin-dependent and insulin-dependent) hypertensive patients: Relationships at baseline and after treatment by the angiotensin converting enzyme inhibitor trandolapril. Am J Hypertens 11:1065-1073, 1998
610. Garg SK, Chase HP, Icaza G, Rothman RL, Osberg I, Carmain JA: 24-hour ambulatory blood pressure and renal disease in young subjects with type I diabetes. J Diabetes Complications 11:263-267, 1997
611. Chau NP, Bauduceau B, Chanudet X, Larroque P, Gautier D: Ambulatory blood pressure in diabetic subjects. Am J Hypertens 7:487-491, 1994
612. Palatini P, Graniero GR, Canali C, Santonastaso M, Mos L, Piccolo D, D’Este D, Berton G, Zanata G, De Venuto G, et al: Relationship between albumin excretion rate, ambulatory blood pressure and left ventricular hypertrophy in mild hypertension. J Hypertens 13:1796-1800, 1995
613. Hansen HP, Rossing P, Tarnow L, Nielsen FS, Jensen BR, Parving HH: Circadian rhythm of arterial blood pressure and albuminuria in diabetic nephropathy. Kidney Int 50:579-585, 1996
614. Martinez-Vea A, Valero FA, Bardaji A, Gutierrez C, Broch M, Garcia C, Richart C, Oliver JA: Left ventricular hypertrophy in hypertensive patients with autosomal dominant polycystic kidney disease: Influence of blood pressure and humoral and neurohormonal factors. Am J Nephrol 20:193-200, 2000
615. Tucker B, Fabbian F, Giles M, Johnston A, Baker LR: Reduction of left ventricular mass index with blood pressure reduction in chronic renal failure. Clin Nephrol 52:377-382, 1999
616. Stefanski A, Schmidt KG, Waldherr R, Ritz E: Early increase in blood pressure and diastolic left ventricular malfunction in patients with glomerulonephritis. Kidney Int 50:1321-1326, 1996
617. Szelestei T, Kovacs T, Barta J, Nagy J: Circadian blood pressure changes and cardiac abnormalities in IgA nephropathy. Am J Nephrol 19:546-551, 1999
618. Covic A, Goldsmith DJA, Georgescu GC, Ackrill P: Relationships between blood pressure variability and left ventricular parameters in hemodialysis and renal transplant patients. Nephrology 4:87-94, 1998
619. Nakano S, Ogihara M, Tamura C, Kitazawa M, Nishizawa M, Kigoshi T, Uchida K: Reversed circadian blood pressure rhythm independently predicts endstage renal failure in non-insulin-dependent diabetes mellitus subjects. J Diabetes Complications 13:224-231, 1999
620. Jacobi J, Rockstroh J, John S, Schreiber M, Schlaich MP, Neumayer HH, Schmieder RE: Prospective analysis of the value of 24-hour ambulatory blood pressure on renal function after kidney transplantation. Transplantation 70:819-827, 2000
621. Verdecchia P, Schillaci G, Borgioni C, Ciucci A, Porcellati C: White-coat hypertension. Lancet 348:1444-1445, 1996 (author reply 1445-1446)
622. Kristensen KS, Hoegholm A: White-coat hypertension. Lancet 348:1444, 1996 (author reply 1445-1446)
623. Rossing P, Tarnow L, Boelskifte S, Jensen BR, Nielsen FS, Parving HH: Differences between nisoldipine and lisinopril on glomerular filtration rates and albuminuria in hypertensive IDDM patients with diabetic nephropathy during the first year of treatment. Diabetes 46:481-487, 1997
624. Svensson P, de Faire U, Sleight P, Yusuf S, Ostergren J: Comparative effects of ramipril on ambulatory and office blood pressures: A HOPE Substudy. Hypertension 38:E28-E32, 2001
625. Messerli FH, White WB, Staessen JA: If only cardiologists did properly measure blood pressure. Blood pressure recordings in daily practice and clinical trials. J Am Coll Cardiol 40:2201-2203, 2002